[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9HDVsvHtin9uaK7uHpELzYLqHjEh02-UkH6-1b9NcFg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":70,"rows":77},"Eastern Cooperative Oncology Group",[4],178,false,12,41,41930,16,21,[14,17,19,22,24,26,29,32],{"name":15,"count":16},"Leukemia",20,{"name":18,"count":16},"Lymphoma",{"name":20,"count":21},"Breast Cancer",19,{"name":23,"count":11},"Lung Cancer",{"name":25,"count":11},"Head and Neck Cancer",{"name":27,"count":28},"Prostate Cancer",13,{"name":30,"count":31},"Melanoma (Skin)",11,{"name":33,"count":31},"Colorectal Cancer",[35,40,45,50,55,60,65],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT01415752","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","2023-02-25","rituximab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05628623","Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment","2026-02","Cytarabine",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT00978458","Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma","2026-12-31","temozolomide",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07085728","Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","2027-02-01","Cyclophosphamide",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05289687","Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL","2027-06-30","Daratumumab \u002F Hyaluronidase",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06724237","Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy","2028-04-30","High Dose Chemotherapy",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT07040280","Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma","2029-02-01","Sulforaphane",[71,72,73,74,75,76],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[78,117,144,162,197,432,508,554,572,590,608,628,646,668,686,704,777,1042,1135,1233,1314,1390,1464,1521,1582,1628,1693,1745,1792,1848,1890,1924,1972,2006,2037,2071,2109,2135,2161,2186,2208,2230,2266,2288,2320,2342,2364,2386,2408,2430,2452,2474,2492,2510,2528,2546,2564,2587,2612,2630,2648,2666,2684,2702,2720,2738,2760,2778,2804,2822,2840,2858,2876,2894,2917,2943,2961,2979,3003,3021,3039,3084,3113,3139,3165,3187,3209,3231,3257,3279,3301,3332,3350,3368,3392,3410,3428,3446,3464,3482,3500,3518,3543,3565,3583,3601,3619,3637,3655,3673,3696,3718,3740,3762,3780,3798,3816,3834,3852,3870,3888,3906,3924,3942,3966,3984,4002,4020,4038,4056,4074,4097,4120,4142,4160,4183,4207,4225,4248,4266,4292,4310,4334,4352,4370,4388,4410,4435,4457,4475,4493,4511,4529,4547,4576,4594,4681,4781,4832,4885,4938,4976,5015,5045,5071,5093,5115,5142,5164,5186,5208,5230,5255,5273,5291,5309],{"intervention":49,"totalTrials":79,"cells":80},2,{"EARLY_PHASE1":81,"PHASE1":84,"PHASE2":86,"PHASE3":101,"PHASE4":113,"NA":115},{"trials":82,"activeCount":83},[],0,{"trials":85,"activeCount":83},[],{"trials":87,"activeCount":83},[88],{"nctId":89,"briefTitle":90,"status":91,"phases":92,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":99},"NCT00080938","Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer","COMPLETED",[73],"2008-08","2009-02","2005-12-20",26,[23,98],"Metastatic Cancer",[100],"Temozolomide",{"trials":102,"activeCount":112,"soonestReadout":48},[103],{"nctId":46,"briefTitle":47,"status":104,"phases":105,"primaryCompletion":48,"completion":48,"start":106,"enrollment":107,"conditions":108,"interventions":111},"ACTIVE_NOT_RECRUITING",[74],"2009-11-17",540,[109,110],"Brain and Central Nervous System Tumors","Neurotoxicity",[49],1,{"trials":114,"activeCount":83},[],{"trials":116,"activeCount":83},[],{"intervention":64,"totalTrials":112,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":140,"NA":142},{"trials":120,"activeCount":83},[],{"trials":122,"activeCount":83},[],{"trials":124,"activeCount":83},[],{"trials":126,"activeCount":112,"soonestReadout":63},[127],{"nctId":61,"briefTitle":62,"status":128,"phases":129,"primaryCompletion":63,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":138},"RECRUITING",[74],"2033-12-01","2025-01-30",294,[134,135,136,137],"Anaplastic Large Cell Lymphoma, ALK-Negative","Follicular Helper T-Cell Lymphoma","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","Peripheral T-Cell Lymphoma, Not Otherwise Specified",[64,139],"Stem Cell Mobilization Therapy",{"trials":141,"activeCount":83},[],{"trials":143,"activeCount":83},[],{"intervention":139,"totalTrials":112,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":158,"NA":160},{"trials":147,"activeCount":83},[],{"trials":149,"activeCount":83},[],{"trials":151,"activeCount":83},[],{"trials":153,"activeCount":112,"soonestReadout":63},[154],{"nctId":61,"briefTitle":62,"status":128,"phases":155,"primaryCompletion":63,"completion":130,"start":131,"enrollment":132,"conditions":156,"interventions":157},[74],[134,135,136,137],[64,139],{"trials":159,"activeCount":83},[],{"trials":161,"activeCount":83},[],{"intervention":163,"totalTrials":79,"cells":164},"Bortezomib",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":166,"activeCount":83},[],{"trials":168,"activeCount":83},[],{"trials":170,"activeCount":79,"soonestReadout":38},[171,180],{"nctId":51,"briefTitle":52,"status":104,"phases":172,"primaryCompletion":53,"completion":53,"start":173,"enrollment":174,"conditions":175,"interventions":177},[73],"2025-08-11",74,[176],"Myeloma Multiple",[54,163,178,179],"Dexamethasone","Daratumumab-hyaluronidase",{"nctId":36,"briefTitle":37,"status":104,"phases":181,"primaryCompletion":38,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},[73],"2031-09","2012-08-09",373,[18,186],"Mantle Cell Lymphoma",[39,188,189,190],"Bendamustine","bortezomib","lenalidomide",{"trials":192,"activeCount":83},[],{"trials":194,"activeCount":83},[],{"trials":196,"activeCount":83},[],{"intervention":198,"totalTrials":21,"cells":199},"cyclophosphamide",{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":333,"PHASE4":428,"NA":430},{"trials":201,"activeCount":83},[],{"trials":203,"activeCount":83},[],{"trials":205,"activeCount":112,"soonestReadout":53},[206,220,230,234,247,259,273,287,300,311,323],{"nctId":207,"briefTitle":208,"status":91,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":215},"NCT00217425","Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms",[73],"2012-04","2014-03","2006-09-14",46,[18],[216,198,217,218,219],"bevacizumab","doxorubicin","prednisone","vincristine",{"nctId":221,"briefTitle":222,"status":91,"phases":223,"primaryCompletion":224,"start":225,"conditions":226,"interventions":227},"NCT00006390","Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia",[73],"2004-12","2001-07-05",[15],[228,229,198],"alemtuzumab","filgrastim",{"nctId":51,"briefTitle":52,"status":104,"phases":231,"primaryCompletion":53,"completion":53,"start":173,"enrollment":174,"conditions":232,"interventions":233},[73],[176],[54,163,178,179],{"nctId":235,"briefTitle":236,"status":237,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":11,"conditions":242,"interventions":243},"NCT00060346","Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia","TERMINATED",[73],"2011-12","2012-08","2004-10-05",[18],[39,198,244,245,246],"Doxorubicin","Prednisone","Vincristine",{"nctId":248,"briefTitle":249,"status":91,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},"NCT00074282","Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL",[73],"2017-12-09","2018-05-06","2005-04-14",102,[15],[39,198,257,258],"pentostatin","Alemtuzumab",{"nctId":260,"briefTitle":261,"status":91,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"conditions":266,"interventions":267},"NCT00005962","Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia",[73],"2005-10","2007-06","2000-10-04",[15],[268,198,269,270,271,272],"sargramostim","cytarabine","gemtuzumab ozogamicin","liposomal daunorubicin citrate","topotecan hydrochloride",{"nctId":274,"briefTitle":275,"status":91,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":282},"NCT00274924","Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma",[73],"2013-06","2019-03","2006-09-26",100,[18],[229,39,283,198,284,285,286,218,219],"carboplatin","doxorubicin hydrochloride","etoposide","ifosfamide",{"nctId":288,"briefTitle":289,"status":91,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"conditions":294,"interventions":296},"NCT00014508","Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma",[73],"2007-02","2011-05-27","2001-11-19",[295],"Multiple Myeloma and Plasma Cell Neoplasm",[268,198,297,298,299],"cyclosporine","fludarabine phosphate","melphalan",{"nctId":301,"briefTitle":302,"status":237,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":309},"NCT00003910","Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia",[73],"2010-12-01","2012-03","1999-09-15",59,[15],[54,310,245],"Methotrexate",{"nctId":312,"briefTitle":313,"status":91,"phases":314,"primaryCompletion":315,"start":316,"enrollment":317,"conditions":318,"interventions":319},"NCT00003388","Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma",[73],"2003-04","1999-07-26",38,[18],[229,198,269,320,321,218,322],"methotrexate","pegylated liposomal doxorubicin hydrochloride","vincristine sulfate",{"nctId":324,"briefTitle":325,"status":91,"phases":326,"primaryCompletion":327,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT00003309","Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer",[73],"2004-03","1999-05-04",33,[109],[229,332,198,285,322],"cisplatin",{"trials":334,"activeCount":83},[335,344,354,369,381,391,407,417],{"nctId":336,"briefTitle":337,"status":91,"phases":338,"primaryCompletion":339,"start":340,"enrollment":341,"conditions":342,"interventions":343},"NCT00003764","Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia",[74],"2005-11","2000-03-09",280,[15],[198,298],{"nctId":345,"briefTitle":346,"status":91,"phases":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT00003150","Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma",[74],"2006-09","1997-12",630,[18],[39,353,198,284,218,322],"CHOP regimen",{"nctId":355,"briefTitle":356,"status":91,"phases":357,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":363},"NCT00003389","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma",[74],"2011-09","2016-05","1999-06-17",854,[18],[244,364,365,366,246,367,368,245,54],"Bleomycin","Vinblastine","Dacarbazine","Mechlorethamine","Etoposide",{"nctId":370,"briefTitle":371,"status":91,"phases":372,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":378},"NCT00049517","Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia",[74],"2009-03","2019-12","2002-12-19",657,[15],[268,379,198,269,270,380],"busulfan","Daunorubicin",{"nctId":382,"briefTitle":383,"status":91,"phases":384,"primaryCompletion":385,"start":386,"enrollment":387,"conditions":388,"interventions":389},"NCT00052923","Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma",[74],"2006-06","2003-03",427,[18],[229,39,390,198,285],"carmustine",{"nctId":392,"briefTitle":393,"status":91,"phases":394,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":398,"interventions":399},"NCT00002514","Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission",[74],"2006-12","1993-05-07",1929,[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],"asparaginase","daunorubicin hydrochloride","dexamethasone","imatinib mesylate","leucovorin calcium","mercaptopurine","thioguanine",{"nctId":408,"briefTitle":409,"status":91,"phases":410,"primaryCompletion":411,"start":412,"enrollment":413,"conditions":414,"interventions":415},"NCT00003519","Combination Chemotherapy in Treating Women With Breast Cancer",[74],"2007-01","1998-08-20",2778,[20],[198,416,284],"docetaxel",{"nctId":418,"briefTitle":419,"status":91,"phases":420,"primaryCompletion":421,"completion":422,"start":423,"conditions":424,"interventions":425},"NCT00004125","Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes",[74],"2007-05","2016-11","1999-11-16",[20],[198,416,284,426,427],"paclitaxel","tamoxifen citrate",{"trials":429,"activeCount":83},[],{"trials":431,"activeCount":83},[],{"intervention":269,"totalTrials":433,"cells":434},8,{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":472,"PHASE4":504,"NA":506},{"trials":436,"activeCount":83},[],{"trials":438,"activeCount":83},[],{"trials":440,"activeCount":112,"soonestReadout":43},[441,453,457,461],{"nctId":41,"briefTitle":42,"status":442,"phases":443,"primaryCompletion":43,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},"NOT_YET_RECRUITING",[73],"2027-02","2024-10-23",184,[448],"Leukemia, Myeloid, Acute",[44,450,451,452],"Venetoclax","CPX-351","Azacitidine",{"nctId":260,"briefTitle":261,"status":91,"phases":454,"primaryCompletion":263,"completion":264,"start":265,"conditions":455,"interventions":456},[73],[15],[268,198,269,270,271,272],{"nctId":312,"briefTitle":313,"status":91,"phases":458,"primaryCompletion":315,"start":316,"enrollment":317,"conditions":459,"interventions":460},[73],[18],[229,198,269,320,321,218,322],{"nctId":462,"briefTitle":463,"status":237,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":96,"conditions":467,"interventions":468},"NCT00335140","Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma",[73],"2015-07","2007-08-23",[18],[469,44,178,470,310,471,246],"Rituximab","Leucovorin","Procarbazine",{"trials":473,"activeCount":83},[474,485,489,493],{"nctId":475,"briefTitle":476,"status":91,"phases":477,"primaryCompletion":327,"start":478,"enrollment":479,"conditions":480,"interventions":481},"NCT00002868","Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",[74],"1997-11-20",744,[15],[229,482,379,269,285,483,484],"recombinant interferon alfa","hydroxyurea","idarubicin",{"nctId":370,"briefTitle":371,"status":91,"phases":486,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":487,"interventions":488},[74],[15],[268,379,198,269,270,380],{"nctId":392,"briefTitle":393,"status":91,"phases":490,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":491,"interventions":492},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"nctId":494,"briefTitle":495,"status":91,"phases":496,"primaryCompletion":497,"start":498,"enrollment":499,"conditions":500,"interventions":502},"NCT00046930","Daunorubicin & Cytarabine +\u002F- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia",[74],"2009-06","2002-09-17",449,[15,501],"Myelodysplastic Syndromes",[229,268,269,401,503],"zosuquidar trihydrochloride",{"trials":505,"activeCount":83},[],{"trials":507,"activeCount":83},[],{"intervention":402,"totalTrials":509,"cells":510},5,{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":525,"PHASE4":550,"NA":552},{"trials":512,"activeCount":83},[],{"trials":514,"activeCount":83},[],{"trials":516,"activeCount":112,"soonestReadout":53},[517,521],{"nctId":51,"briefTitle":52,"status":104,"phases":518,"primaryCompletion":53,"completion":53,"start":173,"enrollment":174,"conditions":519,"interventions":520},[73],[176],[54,163,178,179],{"nctId":462,"briefTitle":463,"status":237,"phases":522,"primaryCompletion":465,"completion":465,"start":466,"enrollment":96,"conditions":523,"interventions":524},[73],[18],[469,44,178,470,310,471,246],{"trials":526,"activeCount":83},[527,531,542],{"nctId":392,"briefTitle":393,"status":91,"phases":528,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":529,"interventions":530},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"nctId":532,"briefTitle":533,"status":91,"phases":534,"primaryCompletion":385,"start":535,"enrollment":536,"conditions":537,"interventions":540},"NCT00060398","Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer",[74],"2004-09-29",282,[538,539,27],"Anemia","Fatigue",[541,402],"epoetin alfa",{"nctId":543,"briefTitle":544,"status":91,"phases":545,"primaryCompletion":315,"start":546,"conditions":547,"interventions":548},"NCT00002878","Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma",[74],"1997-06-30",[295],[402,284,549,322],"valspodar",{"trials":551,"activeCount":83},[],{"trials":553,"activeCount":83},[],{"intervention":450,"totalTrials":112,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":557,"activeCount":83},[],{"trials":559,"activeCount":83},[],{"trials":561,"activeCount":112,"soonestReadout":43},[562],{"nctId":41,"briefTitle":42,"status":442,"phases":563,"primaryCompletion":43,"completion":444,"start":445,"enrollment":446,"conditions":564,"interventions":565},[73],[448],[44,450,451,452],{"trials":567,"activeCount":83},[],{"trials":569,"activeCount":83},[],{"trials":571,"activeCount":83},[],{"intervention":451,"totalTrials":112,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":584,"PHASE4":586,"NA":588},{"trials":575,"activeCount":83},[],{"trials":577,"activeCount":83},[],{"trials":579,"activeCount":112,"soonestReadout":43},[580],{"nctId":41,"briefTitle":42,"status":442,"phases":581,"primaryCompletion":43,"completion":444,"start":445,"enrollment":446,"conditions":582,"interventions":583},[73],[448],[44,450,451,452],{"trials":585,"activeCount":83},[],{"trials":587,"activeCount":83},[],{"trials":589,"activeCount":83},[],{"intervention":452,"totalTrials":112,"cells":591},{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":593,"activeCount":83},[],{"trials":595,"activeCount":83},[],{"trials":597,"activeCount":112,"soonestReadout":43},[598],{"nctId":41,"briefTitle":42,"status":442,"phases":599,"primaryCompletion":43,"completion":444,"start":445,"enrollment":446,"conditions":600,"interventions":601},[73],[448],[44,450,451,452],{"trials":603,"activeCount":83},[],{"trials":605,"activeCount":83},[],{"trials":607,"activeCount":83},[],{"intervention":59,"totalTrials":112,"cells":609},{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":622,"PHASE4":624,"NA":626},{"trials":611,"activeCount":83},[],{"trials":613,"activeCount":83},[],{"trials":615,"activeCount":112,"soonestReadout":58},[616],{"nctId":56,"briefTitle":57,"status":128,"phases":617,"primaryCompletion":58,"completion":58,"start":618,"enrollment":16,"conditions":619,"interventions":621},[73],"2023-05-25",[620],"T-cell Acute Lymphoblastic Leukemia",[59,59,59,59],{"trials":623,"activeCount":83},[],{"trials":625,"activeCount":83},[],{"trials":627,"activeCount":83},[],{"intervention":179,"totalTrials":112,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":631,"activeCount":83},[],{"trials":633,"activeCount":83},[],{"trials":635,"activeCount":112,"soonestReadout":53},[636],{"nctId":51,"briefTitle":52,"status":104,"phases":637,"primaryCompletion":53,"completion":53,"start":173,"enrollment":174,"conditions":638,"interventions":639},[73],[176],[54,163,178,179],{"trials":641,"activeCount":83},[],{"trials":643,"activeCount":83},[],{"trials":645,"activeCount":83},[],{"intervention":69,"totalTrials":112,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":662,"PHASE4":664,"NA":666},{"trials":649,"activeCount":83},[],{"trials":651,"activeCount":83},[],{"trials":653,"activeCount":112,"soonestReadout":68},[654],{"nctId":66,"briefTitle":67,"status":442,"phases":655,"primaryCompletion":68,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":661},[73],"2029-08-01","2025-10-31",120,[660],"Melanoma",[69],{"trials":663,"activeCount":83},[],{"trials":665,"activeCount":83},[],{"trials":667,"activeCount":83},[],{"intervention":188,"totalTrials":112,"cells":669},{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":680,"PHASE4":682,"NA":684},{"trials":671,"activeCount":83},[],{"trials":673,"activeCount":83},[],{"trials":675,"activeCount":112,"soonestReadout":38},[676],{"nctId":36,"briefTitle":37,"status":104,"phases":677,"primaryCompletion":38,"completion":182,"start":183,"enrollment":184,"conditions":678,"interventions":679},[73],[18,186],[39,188,189,190],{"trials":681,"activeCount":83},[],{"trials":683,"activeCount":83},[],{"trials":685,"activeCount":83},[],{"intervention":190,"totalTrials":112,"cells":687},{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":698,"PHASE4":700,"NA":702},{"trials":689,"activeCount":83},[],{"trials":691,"activeCount":83},[],{"trials":693,"activeCount":112,"soonestReadout":38},[694],{"nctId":36,"briefTitle":37,"status":104,"phases":695,"primaryCompletion":38,"completion":182,"start":183,"enrollment":184,"conditions":696,"interventions":697},[73],[18,186],[39,188,189,190],{"trials":699,"activeCount":83},[],{"trials":701,"activeCount":83},[],{"trials":703,"activeCount":83},[],{"intervention":39,"totalTrials":705,"cells":706},10,{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":741,"PHASE4":761,"NA":763},{"trials":708,"activeCount":83},[],{"trials":710,"activeCount":83},[],{"trials":712,"activeCount":112,"soonestReadout":38},[713,721,725,729,733,737],{"nctId":714,"briefTitle":715,"status":91,"phases":716,"completion":717,"start":718,"conditions":719,"interventions":720},"NCT00005609","Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia",[73],"2004-02","2000-04",[18],[39],{"nctId":235,"briefTitle":236,"status":237,"phases":722,"primaryCompletion":239,"completion":240,"start":241,"enrollment":11,"conditions":723,"interventions":724},[73],[18],[39,198,244,245,246],{"nctId":248,"briefTitle":249,"status":91,"phases":726,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":727,"interventions":728},[73],[15],[39,198,257,258],{"nctId":274,"briefTitle":275,"status":91,"phases":730,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":731,"interventions":732},[73],[18],[229,39,283,198,284,285,286,218,219],{"nctId":36,"briefTitle":37,"status":104,"phases":734,"primaryCompletion":38,"completion":182,"start":183,"enrollment":184,"conditions":735,"interventions":736},[73],[18,186],[39,188,189,190],{"nctId":462,"briefTitle":463,"status":237,"phases":738,"primaryCompletion":465,"completion":465,"start":466,"enrollment":96,"conditions":739,"interventions":740},[73],[18],[469,44,178,470,310,471,246],{"trials":742,"activeCount":83},[743,747,757],{"nctId":345,"briefTitle":346,"status":91,"phases":744,"completion":348,"start":349,"enrollment":350,"conditions":745,"interventions":746},[74],[18],[39,353,198,284,218,322],{"nctId":748,"briefTitle":749,"status":91,"phases":750,"primaryCompletion":751,"completion":752,"start":753,"enrollment":754,"conditions":755,"interventions":756},"NCT00075946","Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma",[74],"2013-09","2021-08","2004-01-23",545,[18],[39],{"nctId":382,"briefTitle":383,"status":91,"phases":758,"primaryCompletion":385,"start":386,"enrollment":387,"conditions":759,"interventions":760},[74],[18],[229,39,390,198,285],{"trials":762,"activeCount":83},[],{"trials":764,"activeCount":83},[765],{"nctId":766,"briefTitle":767,"status":91,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":773},"NCT01406782","DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402",[],"2012-01-13","2011-12-13",200,[18],[39,774,775,776],"DNA analysis","gene expression analysis","polymerase chain reaction",{"intervention":426,"totalTrials":96,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":977,"PHASE4":1038,"NA":1040},{"trials":780,"activeCount":83},[],{"trials":782,"activeCount":83},[],{"trials":784,"activeCount":83},[785,794,805,814,823,831,842,854,864,874,886,899,907,920,929,937,945,956,968],{"nctId":786,"briefTitle":787,"status":91,"phases":788,"primaryCompletion":789,"start":790,"enrollment":791,"conditions":792,"interventions":793},"NCT00002826","Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer",[73],"2003-11","1997-08-14",36,[20],[426,549],{"nctId":795,"briefTitle":796,"status":91,"phases":797,"primaryCompletion":798,"completion":240,"start":799,"enrollment":800,"conditions":801,"interventions":802},"NCT00062010","Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer",[73],"2011-05","2004-05-26",37,[23],[803,804,426],"interferon alpha","13-cis-retinoic acid",{"nctId":806,"briefTitle":807,"status":91,"phases":808,"primaryCompletion":809,"start":810,"conditions":811,"interventions":812},"NCT00006004","Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer",[73],"2005-01","2000-08-22",[23],[283,332,813,426],"gemcitabine hydrochloride",{"nctId":815,"briefTitle":816,"status":91,"phases":817,"primaryCompletion":818,"start":819,"enrollment":820,"conditions":821,"interventions":822},"NCT00002632","Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer",[73],"2002-05","1995-05-30",32,[25],[426],{"nctId":824,"briefTitle":825,"status":91,"phases":826,"primaryCompletion":827,"start":828,"conditions":829,"interventions":830},"NCT00003206","Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer",[73],"2001-07","1999-10-06",[25],[283,426],{"nctId":832,"briefTitle":833,"status":91,"phases":834,"primaryCompletion":835,"start":836,"enrollment":837,"conditions":838,"interventions":841},"NCT00003518","Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors",[73],"2002-07","1999-01-25",44,[839,840],"Ovarian Cancer","Testicular Germ Cell Tumor",[813,426],{"nctId":843,"briefTitle":844,"status":91,"phases":845,"primaryCompletion":846,"start":847,"conditions":848,"interventions":849},"NCT00005847","Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",[73],"2004-07","2001-04-05",[27],[482,850,851,852,426,853],"estramustine phosphate sodium","isotretinoin","mitoxantrone hydrochloride","vinorelbine ditartrate",{"nctId":855,"briefTitle":856,"status":91,"phases":857,"primaryCompletion":858,"completion":240,"start":859,"enrollment":213,"conditions":860,"interventions":863},"NCT00010257","Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma",[73],"2008-11","2001-06-19",[861,862],"Thymoma","Thymic Carcinoma",[283,426],{"nctId":865,"briefTitle":866,"status":91,"phases":867,"primaryCompletion":868,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT00077129","Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer",[73],"2006-08","2006-06-01",22,[872],"Kidney Cancer",[283,426],{"nctId":875,"briefTitle":876,"status":91,"phases":877,"primaryCompletion":385,"start":878,"enrollment":329,"conditions":879,"interventions":881},"NCT00003008","Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma",[73],"1997-12-15",[880],"Sarcoma",[882,883,426,884,885],"indinavir sulfate","nelfinavir mesylate","ritonavir","saquinavir mesylate",{"nctId":887,"briefTitle":888,"status":91,"phases":889,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":894,"interventions":897},"NCT00033657","Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer",[73],"2009-09","2009-10","2002-08-15",97,[895,896],"Esophageal Cancer","Gastric Cancer",[332,898,426],"irinotecan hydrochloride",{"nctId":900,"briefTitle":901,"status":91,"phases":902,"primaryCompletion":903,"start":904,"conditions":905,"interventions":906},"NCT00003614","Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer",[73],"2005-04","1999-02-04",[27],[850,426],{"nctId":908,"briefTitle":909,"status":91,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":916},"NCT01084083","Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III\u002FIV Oropharynx Cancer",[73],"2015-01","2010-08-11",90,[25,915],"Precancerous Condition",[917,918,919],"cetuximab","Paclitaxel","Cisplatin",{"nctId":921,"briefTitle":922,"status":91,"phases":923,"primaryCompletion":924,"completion":925,"start":926,"conditions":927,"interventions":928},"NCT00014118","Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer",[73],"2007-03","2009-05","2001-06-06",[25],[283,426],{"nctId":930,"briefTitle":931,"status":91,"phases":932,"primaryCompletion":933,"start":934,"conditions":935,"interventions":936},"NCT00002922","Paclitaxel in Treating Patients With Advanced Head and Neck Cancer",[73],"2001-09","1997-02-21",[25],[426],{"nctId":938,"briefTitle":939,"status":91,"phases":940,"completion":846,"start":941,"conditions":942,"interventions":943},"NCT00003881","Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer",[73],"1999-05",[23],[944,283,426],"trastuzumab",{"nctId":946,"briefTitle":947,"status":91,"phases":948,"primaryCompletion":949,"completion":950,"start":951,"enrollment":174,"conditions":952,"interventions":953},"NCT00089297","Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer",[73],"2010-02","2011-02","2005-01-06",[25],[954,955,918],"Cetuximab","Carboplatin",{"nctId":957,"briefTitle":958,"status":91,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"conditions":963,"interventions":967},"NCT00005644","Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function",[73],"2003-02","2007-06-15","2001-01-02",[964,965,966],"Bladder Cancer","Transitional Cell Cancer of the Renal Pelvis and Ureter","Urethral Cancer",[813,426],{"nctId":969,"briefTitle":970,"status":91,"phases":971,"primaryCompletion":972,"start":973,"enrollment":974,"conditions":975,"interventions":976},"NCT00003237","Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach",[73],"2003-10","1998-06-22",55,[895,896],[332,426],{"trials":978,"activeCount":83},[979,986,996,1005,1014,1024,1028],{"nctId":980,"briefTitle":981,"status":91,"phases":982,"primaryCompletion":868,"start":983,"enrollment":132,"conditions":984,"interventions":985},"NCT00003235","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed",[74],"1998-06-01",[23],[283,426],{"nctId":987,"briefTitle":988,"status":91,"phases":989,"primaryCompletion":990,"start":991,"enrollment":992,"conditions":993,"interventions":994},"NCT00003376","Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium",[74],"2005-09","1998-12-03",330,[964,965,966],[283,332,284,320,426,995],"vinblastine",{"nctId":997,"briefTitle":998,"status":91,"phases":999,"primaryCompletion":1000,"completion":925,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT00028990","Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",[74],"2006-11","2002-01-29",722,[20],[216,918],{"nctId":1006,"briefTitle":1007,"status":91,"phases":1008,"completion":1009,"start":1010,"conditions":1011,"interventions":1012},"NCT00002888","Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer",[74],"2004-08","1997-03",[25],[332,1013,426],"fluorouracil",{"nctId":1015,"briefTitle":1016,"status":91,"phases":1017,"primaryCompletion":1018,"completion":961,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1022},"NCT00003701","Combination Chemotherapy in Treating Patients With Bladder Cancer",[74],"2001-08","1999-04-02",490,[964,966],[283,332,284,320,426,1023],"vinblastine sulfate",{"nctId":418,"briefTitle":419,"status":91,"phases":1025,"primaryCompletion":421,"completion":422,"start":423,"conditions":1026,"interventions":1027},[74],[20],[198,416,284,426,427],{"nctId":1029,"briefTitle":1030,"status":91,"phases":1031,"primaryCompletion":1032,"completion":1033,"start":1034,"enrollment":1035,"conditions":1036,"interventions":1037},"NCT00003592","Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer",[74],"2000-08","2004-03-02","1999-04-22",230,[25],[320,426],{"trials":1039,"activeCount":83},[],{"trials":1041,"activeCount":83},[],{"intervention":283,"totalTrials":1043,"cells":1044},15,{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1117,"PHASE4":1131,"NA":1133},{"trials":1046,"activeCount":83},[],{"trials":1048,"activeCount":83},[],{"trials":1050,"activeCount":83},[1051,1060,1068,1072,1076,1080,1088,1092,1096,1105,1109,1113],{"nctId":1052,"briefTitle":1053,"status":91,"phases":1054,"primaryCompletion":890,"completion":798,"start":1055,"enrollment":820,"conditions":1056,"interventions":1058},"NCT00101283","Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma",[73],"2006-02-23",[1057],"Mesothelioma",[1059,813,283],"pemetrexed disodium",{"nctId":1061,"briefTitle":1062,"status":91,"phases":1063,"primaryCompletion":1064,"start":1065,"conditions":1066,"interventions":1067},"NCT00003864","Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus",[73],"2004-01","1999-09-03",[895],[283,416],{"nctId":806,"briefTitle":807,"status":91,"phases":1069,"primaryCompletion":809,"start":810,"conditions":1070,"interventions":1071},[73],[23],[283,332,813,426],{"nctId":824,"briefTitle":825,"status":91,"phases":1073,"primaryCompletion":827,"start":828,"conditions":1074,"interventions":1075},[73],[25],[283,426],{"nctId":274,"briefTitle":275,"status":91,"phases":1077,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":1078,"interventions":1079},[73],[18],[229,39,283,198,284,285,286,218,219],{"nctId":1081,"briefTitle":1082,"status":1083,"phases":1084,"start":264,"enrollment":83,"conditions":1085,"interventions":1086},"NCT00469976","Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer","WITHDRAWN",[73],[23],[216,283,1087,813],"enzastaurin hydrochloride",{"nctId":855,"briefTitle":856,"status":91,"phases":1089,"primaryCompletion":858,"completion":240,"start":859,"enrollment":213,"conditions":1090,"interventions":1091},[73],[861,862],[283,426],{"nctId":865,"briefTitle":866,"status":91,"phases":1093,"primaryCompletion":868,"start":869,"enrollment":870,"conditions":1094,"interventions":1095},[73],[872],[283,426],{"nctId":1097,"briefTitle":1098,"status":91,"phases":1099,"primaryCompletion":1100,"completion":961,"start":1101,"conditions":1102,"interventions":1103},"NCT00041314","Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer",[73],"2005-07","2002-10-04",[23],[283,1104,813],"exisulind",{"nctId":921,"briefTitle":922,"status":91,"phases":1106,"primaryCompletion":924,"completion":925,"start":926,"conditions":1107,"interventions":1108},[73],[25],[283,426],{"nctId":938,"briefTitle":939,"status":91,"phases":1110,"completion":846,"start":941,"conditions":1111,"interventions":1112},[73],[23],[944,283,426],{"nctId":946,"briefTitle":947,"status":91,"phases":1114,"primaryCompletion":949,"completion":950,"start":951,"enrollment":174,"conditions":1115,"interventions":1116},[73],[25],[954,955,918],{"trials":1118,"activeCount":83},[1119,1123,1127],{"nctId":980,"briefTitle":981,"status":91,"phases":1120,"primaryCompletion":868,"start":983,"enrollment":132,"conditions":1121,"interventions":1122},[74],[23],[283,426],{"nctId":987,"briefTitle":988,"status":91,"phases":1124,"primaryCompletion":990,"start":991,"enrollment":992,"conditions":1125,"interventions":1126},[74],[964,965,966],[283,332,284,320,426,995],{"nctId":1015,"briefTitle":1016,"status":91,"phases":1128,"primaryCompletion":1018,"completion":961,"start":1019,"enrollment":1020,"conditions":1129,"interventions":1130},[74],[964,966],[283,332,284,320,426,1023],{"trials":1132,"activeCount":83},[],{"trials":1134,"activeCount":83},[],{"intervention":229,"totalTrials":28,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1152,"PHASE3":1193,"PHASE4":1229,"NA":1231},{"trials":1138,"activeCount":83},[],{"trials":1140,"activeCount":83},[1141],{"nctId":1142,"briefTitle":1143,"status":237,"phases":1144,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":433,"conditions":1148,"interventions":1150},"NCT00052884","Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation",[72],"2007-09","2011-03","2004-01-22",[1149,295],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan",[229,1151,299],"amifostine trihydrate",{"trials":1153,"activeCount":83},[1154,1161,1165,1169,1173,1177,1185],{"nctId":1155,"briefTitle":1156,"status":91,"phases":1157,"completion":1158,"start":349,"conditions":1159,"interventions":1160},"NCT00003172","Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer",[73],"2004-09",[896],[229,482,416,284,1013,483],{"nctId":221,"briefTitle":222,"status":91,"phases":1162,"primaryCompletion":224,"start":225,"conditions":1163,"interventions":1164},[73],[15],[228,229,198],{"nctId":274,"briefTitle":275,"status":91,"phases":1166,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":1167,"interventions":1168},[73],[18],[229,39,283,198,284,285,286,218,219],{"nctId":312,"briefTitle":313,"status":91,"phases":1170,"primaryCompletion":315,"start":316,"enrollment":317,"conditions":1171,"interventions":1172},[73],[18],[229,198,269,320,321,218,322],{"nctId":324,"briefTitle":325,"status":91,"phases":1174,"primaryCompletion":327,"start":328,"enrollment":329,"conditions":1175,"interventions":1176},[73],[109],[229,332,198,285,322],{"nctId":1178,"briefTitle":1179,"status":91,"phases":1180,"primaryCompletion":1181,"start":1182,"conditions":1183,"interventions":1184},"NCT00003353","High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis",[73],"2002-12","1998-11-16",[295],[229,299],{"nctId":1186,"briefTitle":1187,"status":91,"phases":1188,"primaryCompletion":263,"completion":925,"start":1189,"conditions":1190,"interventions":1192},"NCT00049348","Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer",[73],"2003-10-13",[1191],"Pancreatic Cancer",[541,229,332,1013,813],{"trials":1194,"activeCount":83},[1195,1206,1210,1214,1225],{"nctId":1196,"briefTitle":1197,"status":91,"phases":1198,"primaryCompletion":93,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1203},"NCT00003138","Erythropoietin (EPO)+\u002F- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes",[74],"2014-05","1998-03-04",118,[538,501],[1204,1205],"Erythropoietin","Filgrastim",{"nctId":475,"briefTitle":476,"status":91,"phases":1207,"primaryCompletion":327,"start":478,"enrollment":479,"conditions":1208,"interventions":1209},[74],[15],[229,482,379,269,285,483,484],{"nctId":382,"briefTitle":383,"status":91,"phases":1211,"primaryCompletion":385,"start":386,"enrollment":387,"conditions":1212,"interventions":1213},[74],[18],[229,39,390,198,285],{"nctId":1215,"briefTitle":1216,"status":91,"phases":1217,"primaryCompletion":1218,"start":1219,"enrollment":1220,"conditions":1221,"interventions":1222},"NCT00003027","Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma",[74],"2007-07","1997-11-13",482,[30],[1223,229,482,332,1224,995],"aldesleukin","dacarbazine",{"nctId":494,"briefTitle":495,"status":91,"phases":1226,"primaryCompletion":497,"start":498,"enrollment":499,"conditions":1227,"interventions":1228},[74],[15,501],[229,268,269,401,503],{"trials":1230,"activeCount":83},[],{"trials":1232,"activeCount":83},[],{"intervention":813,"totalTrials":8,"cells":1234},{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1300,"PHASE4":1310,"NA":1312},{"trials":1236,"activeCount":83},[],{"trials":1238,"activeCount":83},[],{"trials":1240,"activeCount":83},[1241,1245,1253,1257,1266,1270,1277,1281,1285,1292,1296],{"nctId":1052,"briefTitle":1053,"status":91,"phases":1242,"primaryCompletion":890,"completion":798,"start":1055,"enrollment":820,"conditions":1243,"interventions":1244},[73],[1057],[1059,813,283],{"nctId":1246,"briefTitle":1247,"status":91,"phases":1248,"primaryCompletion":1249,"start":1250,"conditions":1251,"interventions":1252},"NCT00004223","Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer",[73],"2002-10","2000-02-24",[964,965,966],[416,813],{"nctId":806,"briefTitle":807,"status":91,"phases":1254,"primaryCompletion":809,"start":810,"conditions":1255,"interventions":1256},[73],[23],[283,332,813,426],{"nctId":1258,"briefTitle":1259,"status":91,"phases":1260,"primaryCompletion":291,"start":385,"enrollment":1261,"conditions":1262,"interventions":1265},"NCT00357630","Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary",[73],52,[1263,1264],"Carcinoma of Unknown Primary","Pain",[813],{"nctId":1081,"briefTitle":1082,"status":1083,"phases":1267,"start":264,"enrollment":83,"conditions":1268,"interventions":1269},[73],[23],[216,283,1087,813],{"nctId":1271,"briefTitle":1272,"status":91,"phases":1273,"primaryCompletion":1145,"completion":925,"start":1274,"enrollment":213,"conditions":1275,"interventions":1276},"NCT00053209","Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium",[73],"2004-08-10",[964,965,966],[813,1059],{"nctId":832,"briefTitle":833,"status":91,"phases":1278,"primaryCompletion":835,"start":836,"enrollment":837,"conditions":1279,"interventions":1280},[73],[839,840],[813,426],{"nctId":1097,"briefTitle":1098,"status":91,"phases":1282,"primaryCompletion":1100,"completion":961,"start":1101,"conditions":1283,"interventions":1284},[73],[23],[283,1104,813],{"nctId":1286,"briefTitle":1287,"status":91,"phases":1288,"primaryCompletion":818,"start":1289,"conditions":1290,"interventions":1291},"NCT00003810","Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas",[73],"1999-08-11",[1191],[416,813],{"nctId":957,"briefTitle":958,"status":91,"phases":1293,"primaryCompletion":960,"completion":961,"start":962,"conditions":1294,"interventions":1295},[73],[964,965,966],[813,426],{"nctId":1186,"briefTitle":1187,"status":91,"phases":1297,"primaryCompletion":263,"completion":925,"start":1189,"conditions":1298,"interventions":1299},[73],[1191],[541,229,332,1013,813],{"trials":1301,"activeCount":83},[1302],{"nctId":1303,"briefTitle":1304,"status":91,"phases":1305,"primaryCompletion":1306,"start":386,"conditions":1307,"interventions":1308},"NCT00058149","Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[74],"2006-07",[1191],[813,1309],"oxaliplatin",{"trials":1311,"activeCount":83},[],{"trials":1313,"activeCount":83},[],{"intervention":416,"totalTrials":705,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1367,"PHASE4":1386,"NA":1388},{"trials":1317,"activeCount":83},[],{"trials":1319,"activeCount":83},[],{"trials":1321,"activeCount":83},[1322,1326,1338,1342,1346,1355,1359],{"nctId":1155,"briefTitle":1156,"status":91,"phases":1323,"completion":1158,"start":349,"conditions":1324,"interventions":1325},[73],[896],[229,482,416,284,1013,483],{"nctId":1327,"briefTitle":1328,"status":237,"phases":1329,"primaryCompletion":1330,"completion":1331,"start":1332,"enrollment":870,"conditions":1333,"interventions":1334},"NCT00551759","Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer",[73],"2011-10","2014-02","2008-10-02",[895],[1335,1336,954,1337],"5-Fluorouracil","Oxaliplatin","Docetaxel",{"nctId":1061,"briefTitle":1062,"status":91,"phases":1339,"primaryCompletion":1064,"start":1065,"conditions":1340,"interventions":1341},[73],[895],[283,416],{"nctId":1246,"briefTitle":1247,"status":91,"phases":1343,"primaryCompletion":1249,"start":1250,"conditions":1344,"interventions":1345},[73],[964,965,966],[416,813],{"nctId":1347,"briefTitle":1348,"status":91,"phases":1349,"primaryCompletion":497,"completion":1350,"start":1351,"enrollment":1352,"conditions":1353,"interventions":1354},"NCT00042939","Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer",[73],"2009-08","2003-12-09",94,[1191],[917,416,898],{"nctId":1286,"briefTitle":1287,"status":91,"phases":1356,"primaryCompletion":818,"start":1289,"conditions":1357,"interventions":1358},[73],[1191],[416,813],{"nctId":1360,"briefTitle":1361,"status":91,"phases":1362,"primaryCompletion":903,"completion":1363,"start":1364,"conditions":1365,"interventions":1366},"NCT00040807","Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer",[73],"2009-05-01","2002-11-19",[25],[416,898],{"trials":1368,"activeCount":83},[1369,1373,1377],{"nctId":408,"briefTitle":409,"status":91,"phases":1370,"primaryCompletion":411,"start":412,"enrollment":413,"conditions":1371,"interventions":1372},[74],[20],[198,416,284],{"nctId":418,"briefTitle":419,"status":91,"phases":1374,"primaryCompletion":421,"completion":422,"start":423,"conditions":1375,"interventions":1376},[74],[20],[198,416,284,426,427],{"nctId":1378,"briefTitle":1379,"status":91,"phases":1380,"primaryCompletion":224,"start":1381,"conditions":1382,"interventions":1383},"NCT00027859","Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer",[74],"2003-10-08",[27],[416,850,1384,1385],"ketoconazole","therapeutic hydrocortisone",{"trials":1387,"activeCount":83},[],{"trials":1389,"activeCount":83},[],{"intervention":320,"totalTrials":705,"cells":1391},{"EARLY_PHASE1":1392,"PHASE1":1394,"PHASE2":1396,"PHASE3":1442,"PHASE4":1460,"NA":1462},{"trials":1393,"activeCount":83},[],{"trials":1395,"activeCount":83},[],{"trials":1397,"activeCount":83},[1398,1412,1416,1423,1427,1438],{"nctId":1399,"briefTitle":1400,"status":91,"phases":1401,"primaryCompletion":1331,"completion":1402,"start":1403,"enrollment":1404,"conditions":1405,"interventions":1407},"NCT00045305","Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes",[73],"2014-09","2006-10-24",17,[15,501,1406],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[1408,310,1409,1410,1411],"Cyclosporine","Photopheresis","Mycofenolate mofetil","Pentostatin",{"nctId":301,"briefTitle":302,"status":237,"phases":1413,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":1414,"interventions":1415},[73],[15],[54,310,245],{"nctId":1417,"briefTitle":1418,"status":91,"phases":1419,"primaryCompletion":421,"start":1420,"enrollment":791,"conditions":1421,"interventions":1422},"NCT00082797","High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[73],"2005-07-12",[109],[404,320],{"nctId":312,"briefTitle":313,"status":91,"phases":1424,"primaryCompletion":315,"start":316,"enrollment":317,"conditions":1425,"interventions":1426},[73],[18],[229,198,269,320,321,218,322],{"nctId":1428,"briefTitle":1429,"status":237,"phases":1430,"primaryCompletion":1431,"completion":798,"start":1432,"enrollment":1433,"conditions":1434,"interventions":1435},"NCT00057954","Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma",[73],"2008-04","2005-11-09",6,[18],[1411,1436,1437,310],"Cyclosporin","Mycophenolate mofetil",{"nctId":462,"briefTitle":463,"status":237,"phases":1439,"primaryCompletion":465,"completion":465,"start":466,"enrollment":96,"conditions":1440,"interventions":1441},[73],[18],[469,44,178,470,310,471,246],{"trials":1443,"activeCount":83},[1444,1448,1452,1456],{"nctId":987,"briefTitle":988,"status":91,"phases":1445,"primaryCompletion":990,"start":991,"enrollment":992,"conditions":1446,"interventions":1447},[74],[964,965,966],[283,332,284,320,426,995],{"nctId":1015,"briefTitle":1016,"status":91,"phases":1449,"primaryCompletion":1018,"completion":961,"start":1019,"enrollment":1020,"conditions":1450,"interventions":1451},[74],[964,966],[283,332,284,320,426,1023],{"nctId":392,"briefTitle":393,"status":91,"phases":1453,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":1454,"interventions":1455},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"nctId":1029,"briefTitle":1030,"status":91,"phases":1457,"primaryCompletion":1032,"completion":1033,"start":1034,"enrollment":1035,"conditions":1458,"interventions":1459},[74],[25],[320,426],{"trials":1461,"activeCount":83},[],{"trials":1463,"activeCount":83},[],{"intervention":218,"totalTrials":1465,"cells":1466},9,{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1503,"PHASE4":1517,"NA":1519},{"trials":1468,"activeCount":83},[],{"trials":1470,"activeCount":83},[],{"trials":1472,"activeCount":83},[1473,1477,1481,1485,1489,1493],{"nctId":207,"briefTitle":208,"status":91,"phases":1474,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":1475,"interventions":1476},[73],[18],[216,198,217,218,219],{"nctId":235,"briefTitle":236,"status":237,"phases":1478,"primaryCompletion":239,"completion":240,"start":241,"enrollment":11,"conditions":1479,"interventions":1480},[73],[18],[39,198,244,245,246],{"nctId":274,"briefTitle":275,"status":91,"phases":1482,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":1483,"interventions":1484},[73],[18],[229,39,283,198,284,285,286,218,219],{"nctId":301,"briefTitle":302,"status":237,"phases":1486,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":1487,"interventions":1488},[73],[15],[54,310,245],{"nctId":312,"briefTitle":313,"status":91,"phases":1490,"primaryCompletion":315,"start":316,"enrollment":317,"conditions":1491,"interventions":1492},[73],[18],[229,198,269,320,321,218,322],{"nctId":1494,"briefTitle":1495,"status":91,"phases":1496,"primaryCompletion":1497,"start":1498,"enrollment":317,"conditions":1499,"interventions":1501},"NCT00003283","Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma",[73],"2003-09","1998-10-13",[1500],"Thymoma and Thymic Carcinoma",[1502,218],"octreotide acetate",{"trials":1504,"activeCount":83},[1505,1509,1513],{"nctId":345,"briefTitle":346,"status":91,"phases":1506,"completion":348,"start":349,"enrollment":350,"conditions":1507,"interventions":1508},[74],[18],[39,353,198,284,218,322],{"nctId":355,"briefTitle":356,"status":91,"phases":1510,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":1511,"interventions":1512},[74],[18],[244,364,365,366,246,367,368,245,54],{"nctId":392,"briefTitle":393,"status":91,"phases":1514,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":1515,"interventions":1516},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"trials":1518,"activeCount":83},[],{"trials":1520,"activeCount":83},[],{"intervention":285,"totalTrials":433,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1560,"PHASE4":1578,"NA":1580},{"trials":1524,"activeCount":83},[],{"trials":1526,"activeCount":83},[],{"trials":1528,"activeCount":83},[1529,1539,1552,1556],{"nctId":1530,"briefTitle":1531,"status":91,"phases":1532,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":1537,"interventions":1538},"NCT00387699","Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",[73],"2007-10","2014-04","2006-10",79,[23],[216,332,285],{"nctId":1540,"briefTitle":1541,"status":91,"phases":1542,"primaryCompletion":1543,"completion":240,"start":1544,"enrollment":1545,"conditions":1546,"interventions":1548},"NCT00057837","Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[73],"2012-01","2004-07-14",140,[1547],"Extensive Stage Small Cell Lung Cancer",[1549,919,368,1550,1551],"G-CSF","Irinotecan","Topotecan",{"nctId":274,"briefTitle":275,"status":91,"phases":1553,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":1554,"interventions":1555},[73],[18],[229,39,283,198,284,285,286,218,219],{"nctId":324,"briefTitle":325,"status":91,"phases":1557,"primaryCompletion":327,"start":328,"enrollment":329,"conditions":1558,"interventions":1559},[73],[109],[229,332,198,285,322],{"trials":1561,"activeCount":83},[1562,1566,1570,1574],{"nctId":355,"briefTitle":356,"status":91,"phases":1563,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":1564,"interventions":1565},[74],[18],[244,364,365,366,246,367,368,245,54],{"nctId":475,"briefTitle":476,"status":91,"phases":1567,"primaryCompletion":327,"start":478,"enrollment":479,"conditions":1568,"interventions":1569},[74],[15],[229,482,379,269,285,483,484],{"nctId":382,"briefTitle":383,"status":91,"phases":1571,"primaryCompletion":385,"start":386,"enrollment":387,"conditions":1572,"interventions":1573},[74],[18],[229,39,390,198,285],{"nctId":392,"briefTitle":393,"status":91,"phases":1575,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":1576,"interventions":1577},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"trials":1579,"activeCount":83},[],{"trials":1581,"activeCount":83},[],{"intervention":284,"totalTrials":433,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1598,"PHASE4":1624,"NA":1626},{"trials":1585,"activeCount":83},[],{"trials":1587,"activeCount":83},[],{"trials":1589,"activeCount":83},[1590,1594],{"nctId":1155,"briefTitle":1156,"status":91,"phases":1591,"completion":1158,"start":349,"conditions":1592,"interventions":1593},[73],[896],[229,482,416,284,1013,483],{"nctId":274,"briefTitle":275,"status":91,"phases":1595,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":1596,"interventions":1597},[73],[18],[229,39,283,198,284,285,286,218,219],{"trials":1599,"activeCount":83},[1600,1604,1608,1612,1616,1620],{"nctId":345,"briefTitle":346,"status":91,"phases":1601,"completion":348,"start":349,"enrollment":350,"conditions":1602,"interventions":1603},[74],[18],[39,353,198,284,218,322],{"nctId":987,"briefTitle":988,"status":91,"phases":1605,"primaryCompletion":990,"start":991,"enrollment":992,"conditions":1606,"interventions":1607},[74],[964,965,966],[283,332,284,320,426,995],{"nctId":1015,"briefTitle":1016,"status":91,"phases":1609,"primaryCompletion":1018,"completion":961,"start":1019,"enrollment":1020,"conditions":1610,"interventions":1611},[74],[964,966],[283,332,284,320,426,1023],{"nctId":408,"briefTitle":409,"status":91,"phases":1613,"primaryCompletion":411,"start":412,"enrollment":413,"conditions":1614,"interventions":1615},[74],[20],[198,416,284],{"nctId":418,"briefTitle":419,"status":91,"phases":1617,"primaryCompletion":421,"completion":422,"start":423,"conditions":1618,"interventions":1619},[74],[20],[198,416,284,426,427],{"nctId":543,"briefTitle":544,"status":91,"phases":1621,"primaryCompletion":315,"start":546,"conditions":1622,"interventions":1623},[74],[295],[402,284,549,322],{"trials":1625,"activeCount":83},[],{"trials":1627,"activeCount":83},[],{"intervention":482,"totalTrials":433,"cells":1629},{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1655,"PHASE4":1689,"NA":1691},{"trials":1631,"activeCount":83},[],{"trials":1633,"activeCount":83},[],{"trials":1635,"activeCount":83},[1636,1640,1644],{"nctId":1155,"briefTitle":1156,"status":91,"phases":1637,"completion":1158,"start":349,"conditions":1638,"interventions":1639},[73],[896],[229,482,416,284,1013,483],{"nctId":843,"briefTitle":844,"status":91,"phases":1641,"primaryCompletion":846,"start":847,"conditions":1642,"interventions":1643},[73],[27],[482,850,851,852,426,853],{"nctId":1645,"briefTitle":1646,"status":91,"phases":1647,"primaryCompletion":1535,"start":1648,"conditions":1649,"interventions":1650},"NCT00006385","Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma",[73],"2000-09",[30],[1651,1652,1653,482,268,1654],"MART-1 antigen","gp100 antigen","incomplete Freund's adjuvant","tyrosinase peptide",{"trials":1656,"activeCount":83},[1657,1665,1669,1673,1680],{"nctId":1658,"briefTitle":1659,"status":91,"phases":1660,"primaryCompletion":1497,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1664},"NCT00003444","Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin",[74],"1999-03-29",167,[30],[482],{"nctId":475,"briefTitle":476,"status":91,"phases":1666,"primaryCompletion":327,"start":478,"enrollment":479,"conditions":1667,"interventions":1668},[74],[15],[229,482,379,269,285,483,484],{"nctId":1215,"briefTitle":1216,"status":91,"phases":1670,"primaryCompletion":1218,"start":1219,"enrollment":1220,"conditions":1671,"interventions":1672},[74],[30],[1223,229,482,332,1224,995],{"nctId":1674,"briefTitle":1675,"status":91,"phases":1676,"primaryCompletion":224,"completion":1363,"start":1677,"conditions":1678,"interventions":1679},"NCT00054561","Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[74],"2003-11-26",[25],[482,851],{"nctId":1681,"briefTitle":1682,"status":91,"phases":1683,"primaryCompletion":1684,"start":1685,"conditions":1686,"interventions":1687},"NCT00005966","Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer",[74],"2006-03","2000-10",[872],[482,1688],"thalidomide",{"trials":1690,"activeCount":83},[],{"trials":1692,"activeCount":83},[],{"intervention":268,"totalTrials":1694,"cells":1695},7,{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1727,"PHASE4":1741,"NA":1743},{"trials":1697,"activeCount":83},[],{"trials":1699,"activeCount":83},[],{"trials":1701,"activeCount":83},[1702,1706,1710,1714],{"nctId":260,"briefTitle":261,"status":91,"phases":1703,"primaryCompletion":263,"completion":264,"start":265,"conditions":1704,"interventions":1705},[73],[15],[268,198,269,270,271,272],{"nctId":288,"briefTitle":289,"status":91,"phases":1707,"primaryCompletion":291,"completion":292,"start":293,"conditions":1708,"interventions":1709},[73],[295],[268,198,297,298,299],{"nctId":1645,"briefTitle":1646,"status":91,"phases":1711,"primaryCompletion":1535,"start":1648,"conditions":1712,"interventions":1713},[73],[30],[1651,1652,1653,482,268,1654],{"nctId":1715,"briefTitle":1716,"status":91,"phases":1717,"primaryCompletion":1718,"completion":1719,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT00071981","Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma",[73],"2011-08","2014-01","2005-05-09",175,[30],[1653,1724,1725,268,1726],"melanoma helper peptide vaccine","multi-epitope melanoma peptide vaccine","tetanus peptide melanoma vaccine",{"trials":1728,"activeCount":83},[1729,1733,1737],{"nctId":370,"briefTitle":371,"status":91,"phases":1730,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":1731,"interventions":1732},[74],[15],[268,379,198,269,270,380],{"nctId":392,"briefTitle":393,"status":91,"phases":1734,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":1735,"interventions":1736},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"nctId":494,"briefTitle":495,"status":91,"phases":1738,"primaryCompletion":497,"start":498,"enrollment":499,"conditions":1739,"interventions":1740},[74],[15,501],[229,268,269,401,503],{"trials":1742,"activeCount":83},[],{"trials":1744,"activeCount":83},[],{"intervention":216,"totalTrials":1433,"cells":1746},{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1751,"PHASE3":1782,"PHASE4":1788,"NA":1790},{"trials":1748,"activeCount":83},[],{"trials":1750,"activeCount":83},[],{"trials":1752,"activeCount":83},[1753,1757,1761,1765,1772],{"nctId":1530,"briefTitle":1531,"status":91,"phases":1754,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":1755,"interventions":1756},[73],[23],[216,332,285],{"nctId":207,"briefTitle":208,"status":91,"phases":1758,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":1759,"interventions":1760},[73],[18],[216,198,217,218,219],{"nctId":1081,"briefTitle":1082,"status":1083,"phases":1762,"start":264,"enrollment":83,"conditions":1763,"interventions":1764},[73],[23],[216,283,1087,813],{"nctId":1766,"briefTitle":1767,"status":91,"phases":1768,"completion":348,"start":1769,"conditions":1770,"interventions":1771},"NCT00006786","Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer",[73],"2000-11",[33],[216,1013,898,404],{"nctId":1773,"briefTitle":1774,"status":91,"phases":1775,"primaryCompletion":1776,"completion":1777,"start":1778,"enrollment":1779,"conditions":1780,"interventions":1781},"NCT00098787","Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer",[73],"2013-11","2015-04","2005-09-08",247,[33],[216,1013,898,404,1336],{"trials":1783,"activeCount":83},[1784],{"nctId":997,"briefTitle":998,"status":91,"phases":1785,"primaryCompletion":1000,"completion":925,"start":1001,"enrollment":1002,"conditions":1786,"interventions":1787},[74],[20],[216,918],{"trials":1789,"activeCount":83},[],{"trials":1791,"activeCount":83},[],{"intervention":1013,"totalTrials":1433,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1838,"PHASE4":1844,"NA":1846},{"trials":1795,"activeCount":83},[],{"trials":1797,"activeCount":83},[],{"trials":1799,"activeCount":83},[1800,1804,1808,1830,1834],{"nctId":1155,"briefTitle":1156,"status":91,"phases":1801,"completion":1158,"start":349,"conditions":1802,"interventions":1803},[73],[896],[229,482,416,284,1013,483],{"nctId":1766,"briefTitle":1767,"status":91,"phases":1805,"completion":348,"start":1769,"conditions":1806,"interventions":1807},[73],[33],[216,1013,898,404],{"nctId":1809,"briefTitle":1810,"status":1083,"phases":1811,"primaryCompletion":1812,"start":1812,"enrollment":83,"conditions":1813,"interventions":1828},"NCT02344810","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",[72,73],"2015-03-06",[1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827],"Adenocarcinoma of the Esophagus","Adenocarcinoma of the Gastroesophageal Junction","Diffuse Adenocarcinoma of the Stomach","Gastrointestinal Cancer","Intestinal Adenocarcinoma of the Stomach","Mixed Adenocarcinoma of the Stomach","Stage IIIA Esophageal Cancer","Stage IIIA Gastric Cancer","Stage IIIB Esophageal Cancer","Stage IIIB Gastric Cancer","Stage IIIC Esophageal Cancer","Stage IIIC Gastric Cancer","Stage IV Esophageal Cancer","Stage IV Gastric Cancer",[1829,1309,404,1013],"c-Met inhibitor AMG 337",{"nctId":1773,"briefTitle":1774,"status":91,"phases":1831,"primaryCompletion":1776,"completion":1777,"start":1778,"enrollment":1779,"conditions":1832,"interventions":1833},[73],[33],[216,1013,898,404,1336],{"nctId":1186,"briefTitle":1187,"status":91,"phases":1835,"primaryCompletion":263,"completion":925,"start":1189,"conditions":1836,"interventions":1837},[73],[1191],[541,229,332,1013,813],{"trials":1839,"activeCount":83},[1840],{"nctId":1006,"briefTitle":1007,"status":91,"phases":1841,"completion":1009,"start":1010,"conditions":1842,"interventions":1843},[74],[25],[332,1013,426],{"trials":1845,"activeCount":83},[],{"trials":1847,"activeCount":83},[],{"intervention":404,"totalTrials":1433,"cells":1849},{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1880,"PHASE4":1886,"NA":1888},{"trials":1851,"activeCount":83},[],{"trials":1853,"activeCount":83},[],{"trials":1855,"activeCount":83},[1856,1860,1864,1868,1872],{"nctId":1766,"briefTitle":1767,"status":91,"phases":1857,"completion":348,"start":1769,"conditions":1858,"interventions":1859},[73],[33],[216,1013,898,404],{"nctId":1417,"briefTitle":1418,"status":91,"phases":1861,"primaryCompletion":421,"start":1420,"enrollment":791,"conditions":1862,"interventions":1863},[73],[109],[404,320],{"nctId":1809,"briefTitle":1810,"status":1083,"phases":1865,"primaryCompletion":1812,"start":1812,"enrollment":83,"conditions":1866,"interventions":1867},[72,73],[1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827],[1829,1309,404,1013],{"nctId":1773,"briefTitle":1774,"status":91,"phases":1869,"primaryCompletion":1776,"completion":1777,"start":1778,"enrollment":1779,"conditions":1870,"interventions":1871},[73],[33],[216,1013,898,404,1336],{"nctId":1873,"briefTitle":1874,"status":91,"phases":1875,"primaryCompletion":263,"start":1876,"conditions":1877,"interventions":1878},"NCT00004860","Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer",[73],"2000-10-09",[33],[404,1879],"tegafur-uracil",{"trials":1881,"activeCount":83},[1882],{"nctId":392,"briefTitle":393,"status":91,"phases":1883,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":1884,"interventions":1885},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"trials":1887,"activeCount":83},[],{"trials":1889,"activeCount":83},[],{"intervention":322,"totalTrials":509,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1906,"PHASE4":1920,"NA":1922},{"trials":1893,"activeCount":83},[],{"trials":1895,"activeCount":83},[],{"trials":1897,"activeCount":83},[1898,1902],{"nctId":312,"briefTitle":313,"status":91,"phases":1899,"primaryCompletion":315,"start":316,"enrollment":317,"conditions":1900,"interventions":1901},[73],[18],[229,198,269,320,321,218,322],{"nctId":324,"briefTitle":325,"status":91,"phases":1903,"primaryCompletion":327,"start":328,"enrollment":329,"conditions":1904,"interventions":1905},[73],[109],[229,332,198,285,322],{"trials":1907,"activeCount":83},[1908,1912,1916],{"nctId":345,"briefTitle":346,"status":91,"phases":1909,"completion":348,"start":349,"enrollment":350,"conditions":1910,"interventions":1911},[74],[18],[39,353,198,284,218,322],{"nctId":392,"briefTitle":393,"status":91,"phases":1913,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":1914,"interventions":1915},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"nctId":543,"briefTitle":544,"status":91,"phases":1917,"primaryCompletion":315,"start":546,"conditions":1918,"interventions":1919},[74],[295],[402,284,549,322],{"trials":1921,"activeCount":83},[],{"trials":1923,"activeCount":83},[],{"intervention":244,"totalTrials":509,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1962,"PHASE4":1968,"NA":1970},{"trials":1927,"activeCount":83},[],{"trials":1929,"activeCount":83},[],{"trials":1931,"activeCount":83},[1932,1936,1940,1950],{"nctId":207,"briefTitle":208,"status":91,"phases":1933,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":1934,"interventions":1935},[73],[18],[216,198,217,218,219],{"nctId":235,"briefTitle":236,"status":237,"phases":1937,"primaryCompletion":239,"completion":240,"start":241,"enrollment":11,"conditions":1938,"interventions":1939},[73],[18],[39,198,244,245,246],{"nctId":1941,"briefTitle":1942,"status":91,"phases":1943,"primaryCompletion":798,"completion":240,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1948},"NCT00003907","Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver",[73],"1999-12-15",50,[1947,98],"Liver Cancer",[332,217,1949],"mitomycin",{"nctId":1951,"briefTitle":1952,"status":91,"phases":1953,"primaryCompletion":497,"completion":798,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1959},"NCT00068393","Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma",[73],"2004-02-24",39,[1957,1958],"Metastatic Renal Cell Carcinoma","Renal Cell Carcinoma With Sarcomatoid Features",[244,1960,1549,1961],"Gemcitabine","Neulasta",{"trials":1963,"activeCount":83},[1964],{"nctId":355,"briefTitle":356,"status":91,"phases":1965,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":1966,"interventions":1967},[74],[18],[244,364,365,366,246,367,368,245,54],{"trials":1969,"activeCount":83},[],{"trials":1971,"activeCount":83},[],{"intervention":246,"totalTrials":509,"cells":1973},{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1996,"PHASE4":2002,"NA":2004},{"trials":1975,"activeCount":83},[],{"trials":1977,"activeCount":83},[],{"trials":1979,"activeCount":83},[1980,1984,1988,1992],{"nctId":207,"briefTitle":208,"status":91,"phases":1981,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":1982,"interventions":1983},[73],[18],[216,198,217,218,219],{"nctId":235,"briefTitle":236,"status":237,"phases":1985,"primaryCompletion":239,"completion":240,"start":241,"enrollment":11,"conditions":1986,"interventions":1987},[73],[18],[39,198,244,245,246],{"nctId":274,"briefTitle":275,"status":91,"phases":1989,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":1990,"interventions":1991},[73],[18],[229,39,283,198,284,285,286,218,219],{"nctId":462,"briefTitle":463,"status":237,"phases":1993,"primaryCompletion":465,"completion":465,"start":466,"enrollment":96,"conditions":1994,"interventions":1995},[73],[18],[469,44,178,470,310,471,246],{"trials":1997,"activeCount":83},[1998],{"nctId":355,"briefTitle":356,"status":91,"phases":1999,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":2000,"interventions":2001},[74],[18],[244,364,365,366,246,367,368,245,54],{"trials":2003,"activeCount":83},[],{"trials":2005,"activeCount":83},[],{"intervention":1336,"totalTrials":2007,"cells":2008},4,{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2027,"PHASE4":2033,"NA":2035},{"trials":2010,"activeCount":83},[],{"trials":2012,"activeCount":83},[],{"trials":2014,"activeCount":83},[2015,2019,2023],{"nctId":1327,"briefTitle":1328,"status":237,"phases":2016,"primaryCompletion":1330,"completion":1331,"start":1332,"enrollment":870,"conditions":2017,"interventions":2018},[73],[895],[1335,1336,954,1337],{"nctId":1809,"briefTitle":1810,"status":1083,"phases":2020,"primaryCompletion":1812,"start":1812,"enrollment":83,"conditions":2021,"interventions":2022},[72,73],[1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827],[1829,1309,404,1013],{"nctId":1773,"briefTitle":1774,"status":91,"phases":2024,"primaryCompletion":1776,"completion":1777,"start":1778,"enrollment":1779,"conditions":2025,"interventions":2026},[73],[33],[216,1013,898,404,1336],{"trials":2028,"activeCount":83},[2029],{"nctId":1303,"briefTitle":1304,"status":91,"phases":2030,"primaryCompletion":1306,"start":386,"conditions":2031,"interventions":2032},[74],[1191],[813,1309],{"trials":2034,"activeCount":83},[],{"trials":2036,"activeCount":83},[],{"intervention":298,"totalTrials":2038,"cells":2039},3,{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2061,"PHASE4":2067,"NA":2069},{"trials":2041,"activeCount":83},[],{"trials":2043,"activeCount":83},[],{"trials":2045,"activeCount":83},[2046,2057],{"nctId":2047,"briefTitle":2048,"status":1083,"phases":2049,"enrollment":83,"conditions":2050,"interventions":2054},"NCT00101140","Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission",[73],[2051,2052,2053],"Adult Acute Erythroid Leukemia","Adult Acute Monoblastic and Acute Monocytic Leukemia","Adult Acute Myeloid Leukemia",[2055,298,2056],"anti-thymocyte globulin","thiotepa",{"nctId":288,"briefTitle":289,"status":91,"phases":2058,"primaryCompletion":291,"completion":292,"start":293,"conditions":2059,"interventions":2060},[73],[295],[268,198,297,298,299],{"trials":2062,"activeCount":83},[2063],{"nctId":336,"briefTitle":337,"status":91,"phases":2064,"primaryCompletion":339,"start":340,"enrollment":341,"conditions":2065,"interventions":2066},[74],[15],[198,298],{"trials":2068,"activeCount":83},[],{"trials":2070,"activeCount":83},[],{"intervention":1502,"totalTrials":2038,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2092,"PHASE4":2105,"NA":2107},{"trials":2074,"activeCount":83},[],{"trials":2076,"activeCount":83},[],{"trials":2078,"activeCount":83},[2079,2088],{"nctId":2080,"briefTitle":2081,"status":1083,"phases":2082,"enrollment":83,"conditions":2083,"interventions":2086},"NCT00227773","Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors",[73],[2084,2085],"Gastrointestinal Carcinoid Tumor","Islet Cell Carcinoma",[1502,2087],"vatalanib",{"nctId":1494,"briefTitle":1495,"status":91,"phases":2089,"primaryCompletion":1497,"start":1498,"enrollment":317,"conditions":2090,"interventions":2091},[73],[1500],[1502,218],{"trials":2093,"activeCount":83},[2094],{"nctId":2095,"briefTitle":2096,"status":91,"phases":2097,"primaryCompletion":2098,"start":2099,"enrollment":2100,"conditions":2101,"interventions":2103},"NCT00003057","Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer",[74],"2000-05","1997-03-26",500,[33,2102],"Diarrhea",[2104,1502],"loperamide hydrochloride",{"trials":2106,"activeCount":83},[],{"trials":2108,"activeCount":83},[],{"intervention":995,"totalTrials":2038,"cells":2110},{"EARLY_PHASE1":2111,"PHASE1":2113,"PHASE2":2115,"PHASE3":2117,"PHASE4":2131,"NA":2133},{"trials":2112,"activeCount":83},[],{"trials":2114,"activeCount":83},[],{"trials":2116,"activeCount":83},[],{"trials":2118,"activeCount":83},[2119,2123,2127],{"nctId":987,"briefTitle":988,"status":91,"phases":2120,"primaryCompletion":990,"start":991,"enrollment":992,"conditions":2121,"interventions":2122},[74],[964,965,966],[283,332,284,320,426,995],{"nctId":355,"briefTitle":356,"status":91,"phases":2124,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":2125,"interventions":2126},[74],[18],[244,364,365,366,246,367,368,245,54],{"nctId":1215,"briefTitle":1216,"status":91,"phases":2128,"primaryCompletion":1218,"start":1219,"enrollment":1220,"conditions":2129,"interventions":2130},[74],[30],[1223,229,482,332,1224,995],{"trials":2132,"activeCount":83},[],{"trials":2134,"activeCount":83},[],{"intervention":850,"totalTrials":2038,"cells":2136},{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2151,"PHASE4":2157,"NA":2159},{"trials":2138,"activeCount":83},[],{"trials":2140,"activeCount":83},[],{"trials":2142,"activeCount":83},[2143,2147],{"nctId":843,"briefTitle":844,"status":91,"phases":2144,"primaryCompletion":846,"start":847,"conditions":2145,"interventions":2146},[73],[27],[482,850,851,852,426,853],{"nctId":900,"briefTitle":901,"status":91,"phases":2148,"primaryCompletion":903,"start":904,"conditions":2149,"interventions":2150},[73],[27],[850,426],{"trials":2152,"activeCount":83},[2153],{"nctId":1378,"briefTitle":1379,"status":91,"phases":2154,"primaryCompletion":224,"start":1381,"conditions":2155,"interventions":2156},[74],[27],[416,850,1384,1385],{"trials":2158,"activeCount":83},[],{"trials":2160,"activeCount":83},[],{"intervention":1960,"totalTrials":79,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2167,"PHASE3":2173,"PHASE4":2182,"NA":2184},{"trials":2164,"activeCount":83},[],{"trials":2166,"activeCount":83},[],{"trials":2168,"activeCount":83},[2169],{"nctId":1951,"briefTitle":1952,"status":91,"phases":2170,"primaryCompletion":497,"completion":798,"start":1954,"enrollment":1955,"conditions":2171,"interventions":2172},[73],[1957,1958],[244,1960,1549,1961],{"trials":2174,"activeCount":83},[2175],{"nctId":2176,"briefTitle":2177,"status":91,"phases":2178,"primaryCompletion":925,"completion":925,"start":2179,"enrollment":174,"conditions":2180,"interventions":2181},"NCT00057876","Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer",[74],"2003-08-29",[1191],[1960],{"trials":2183,"activeCount":83},[],{"trials":2185,"activeCount":83},[],{"intervention":549,"totalTrials":79,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2198,"PHASE4":2204,"NA":2206},{"trials":2189,"activeCount":83},[],{"trials":2191,"activeCount":83},[],{"trials":2193,"activeCount":83},[2194],{"nctId":786,"briefTitle":787,"status":91,"phases":2195,"primaryCompletion":789,"start":790,"enrollment":791,"conditions":2196,"interventions":2197},[73],[20],[426,549],{"trials":2199,"activeCount":83},[2200],{"nctId":543,"briefTitle":544,"status":91,"phases":2201,"primaryCompletion":315,"start":546,"conditions":2202,"interventions":2203},[74],[295],[402,284,549,322],{"trials":2205,"activeCount":83},[],{"trials":2207,"activeCount":83},[],{"intervention":483,"totalTrials":79,"cells":2209},{"EARLY_PHASE1":2210,"PHASE1":2212,"PHASE2":2214,"PHASE3":2220,"PHASE4":2226,"NA":2228},{"trials":2211,"activeCount":83},[],{"trials":2213,"activeCount":83},[],{"trials":2215,"activeCount":83},[2216],{"nctId":1155,"briefTitle":1156,"status":91,"phases":2217,"completion":1158,"start":349,"conditions":2218,"interventions":2219},[73],[896],[229,482,416,284,1013,483],{"trials":2221,"activeCount":83},[2222],{"nctId":475,"briefTitle":476,"status":91,"phases":2223,"primaryCompletion":327,"start":478,"enrollment":479,"conditions":2224,"interventions":2225},[74],[15],[229,482,379,269,285,483,484],{"trials":2227,"activeCount":83},[],{"trials":2229,"activeCount":83},[],{"intervention":2231,"totalTrials":79,"cells":2232},"leuprolide acetate",{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2249,"PHASE4":2262,"NA":2264},{"trials":2234,"activeCount":83},[],{"trials":2236,"activeCount":83},[],{"trials":2238,"activeCount":83},[2239],{"nctId":2240,"briefTitle":2241,"status":1083,"phases":2242,"start":2243,"enrollment":83,"conditions":2244,"interventions":2245},"NCT00771017","Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer",[73],"2008-07",[27],[2246,2247,2248,2231],"GVAX prostate cancer vaccine","bicalutamide","goserelin",{"trials":2250,"activeCount":83},[2251],{"nctId":2252,"briefTitle":2253,"status":91,"phases":2254,"primaryCompletion":2255,"start":2256,"conditions":2257,"interventions":2258},"NCT00002881","Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer",[74],"1998-04","1996-10",[27],[2259,2260,2231,2261,1385],"flutamide","goserelin acetate","suramin",{"trials":2263,"activeCount":83},[],{"trials":2265,"activeCount":83},[],{"intervention":1385,"totalTrials":79,"cells":2267},{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2274,"PHASE4":2284,"NA":2286},{"trials":2269,"activeCount":83},[],{"trials":2271,"activeCount":83},[],{"trials":2273,"activeCount":83},[],{"trials":2275,"activeCount":83},[2276,2280],{"nctId":2252,"briefTitle":2253,"status":91,"phases":2277,"primaryCompletion":2255,"start":2256,"conditions":2278,"interventions":2279},[74],[27],[2259,2260,2231,2261,1385],{"nctId":1378,"briefTitle":1379,"status":91,"phases":2281,"primaryCompletion":224,"start":1381,"conditions":2282,"interventions":2283},[74],[27],[416,850,1384,1385],{"trials":2285,"activeCount":83},[],{"trials":2287,"activeCount":83},[],{"intervention":2289,"totalTrials":79,"cells":2290},"fenretinide",{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2306,"PHASE4":2316,"NA":2318},{"trials":2292,"activeCount":83},[],{"trials":2294,"activeCount":83},[],{"trials":2296,"activeCount":83},[2297],{"nctId":2298,"briefTitle":2299,"status":91,"phases":2300,"primaryCompletion":2301,"completion":1033,"start":2302,"enrollment":317,"conditions":2303,"interventions":2304},"NCT00003601","Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome",[73],"2000-03","1999-02-23",[30],[2289,2305],"tretinoin",{"trials":2307,"activeCount":83},[2308],{"nctId":2309,"briefTitle":2310,"status":91,"phases":2311,"primaryCompletion":717,"start":2312,"enrollment":2313,"conditions":2314,"interventions":2315},"NCT00002646","Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer",[74],"1995-10",1500,[20],[2289,427],{"trials":2317,"activeCount":83},[],{"trials":2319,"activeCount":83},[],{"intervention":366,"totalTrials":79,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2338,"NA":2340},{"trials":2323,"activeCount":83},[],{"trials":2325,"activeCount":83},[],{"trials":2327,"activeCount":83},[],{"trials":2329,"activeCount":83},[2330,2334],{"nctId":355,"briefTitle":356,"status":91,"phases":2331,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":2332,"interventions":2333},[74],[18],[244,364,365,366,246,367,368,245,54],{"nctId":1215,"briefTitle":1216,"status":91,"phases":2335,"primaryCompletion":1218,"start":1219,"enrollment":1220,"conditions":2336,"interventions":2337},[74],[30],[1223,229,482,332,1224,995],{"trials":2339,"activeCount":83},[],{"trials":2341,"activeCount":83},[],{"intervention":379,"totalTrials":79,"cells":2343},{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2360,"NA":2362},{"trials":2345,"activeCount":83},[],{"trials":2347,"activeCount":83},[],{"trials":2349,"activeCount":83},[],{"trials":2351,"activeCount":83},[2352,2356],{"nctId":475,"briefTitle":476,"status":91,"phases":2353,"primaryCompletion":327,"start":478,"enrollment":479,"conditions":2354,"interventions":2355},[74],[15],[229,482,379,269,285,483,484],{"nctId":370,"briefTitle":371,"status":91,"phases":2357,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":2358,"interventions":2359},[74],[15],[268,379,198,269,270,380],{"trials":2361,"activeCount":83},[],{"trials":2363,"activeCount":83},[],{"intervention":270,"totalTrials":79,"cells":2365},{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2370,"PHASE3":2376,"PHASE4":2382,"NA":2384},{"trials":2367,"activeCount":83},[],{"trials":2369,"activeCount":83},[],{"trials":2371,"activeCount":83},[2372],{"nctId":260,"briefTitle":261,"status":91,"phases":2373,"primaryCompletion":263,"completion":264,"start":265,"conditions":2374,"interventions":2375},[73],[15],[268,198,269,270,271,272],{"trials":2377,"activeCount":83},[2378],{"nctId":370,"briefTitle":371,"status":91,"phases":2379,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":2380,"interventions":2381},[74],[15],[268,379,198,269,270,380],{"trials":2383,"activeCount":83},[],{"trials":2385,"activeCount":83},[],{"intervention":427,"totalTrials":79,"cells":2387},{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2392,"PHASE3":2394,"PHASE4":2404,"NA":2406},{"trials":2389,"activeCount":83},[],{"trials":2391,"activeCount":83},[],{"trials":2393,"activeCount":83},[],{"trials":2395,"activeCount":83},[2396,2400],{"nctId":2309,"briefTitle":2310,"status":91,"phases":2397,"primaryCompletion":717,"start":2312,"enrollment":2313,"conditions":2398,"interventions":2399},[74],[20],[2289,427],{"nctId":418,"briefTitle":419,"status":91,"phases":2401,"primaryCompletion":421,"completion":422,"start":423,"conditions":2402,"interventions":2403},[74],[20],[198,416,284,426,427],{"trials":2405,"activeCount":83},[],{"trials":2407,"activeCount":83},[],{"intervention":851,"totalTrials":79,"cells":2409},{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2420,"PHASE4":2426,"NA":2428},{"trials":2411,"activeCount":83},[],{"trials":2413,"activeCount":83},[],{"trials":2415,"activeCount":83},[2416],{"nctId":843,"briefTitle":844,"status":91,"phases":2417,"primaryCompletion":846,"start":847,"conditions":2418,"interventions":2419},[73],[27],[482,850,851,852,426,853],{"trials":2421,"activeCount":83},[2422],{"nctId":1674,"briefTitle":1675,"status":91,"phases":2423,"primaryCompletion":224,"completion":1363,"start":1677,"conditions":2424,"interventions":2425},[74],[25],[482,851],{"trials":2427,"activeCount":83},[],{"trials":2429,"activeCount":83},[],{"intervention":401,"totalTrials":79,"cells":2431},{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2436,"PHASE3":2438,"PHASE4":2448,"NA":2450},{"trials":2433,"activeCount":83},[],{"trials":2435,"activeCount":83},[],{"trials":2437,"activeCount":83},[],{"trials":2439,"activeCount":83},[2440,2444],{"nctId":392,"briefTitle":393,"status":91,"phases":2441,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":2442,"interventions":2443},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"nctId":494,"briefTitle":495,"status":91,"phases":2445,"primaryCompletion":497,"start":498,"enrollment":499,"conditions":2446,"interventions":2447},[74],[15,501],[229,268,269,401,503],{"trials":2449,"activeCount":83},[],{"trials":2451,"activeCount":83},[],{"intervention":541,"totalTrials":79,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2464,"PHASE4":2470,"NA":2472},{"trials":2455,"activeCount":83},[],{"trials":2457,"activeCount":83},[],{"trials":2459,"activeCount":83},[2460],{"nctId":1186,"briefTitle":1187,"status":91,"phases":2461,"primaryCompletion":263,"completion":925,"start":1189,"conditions":2462,"interventions":2463},[73],[1191],[541,229,332,1013,813],{"trials":2465,"activeCount":83},[2466],{"nctId":532,"briefTitle":533,"status":91,"phases":2467,"primaryCompletion":385,"start":535,"enrollment":536,"conditions":2468,"interventions":2469},[74],[538,539,27],[541,402],{"trials":2471,"activeCount":83},[],{"trials":2473,"activeCount":83},[],{"intervention":353,"totalTrials":112,"cells":2475},{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2482,"PHASE4":2488,"NA":2490},{"trials":2477,"activeCount":83},[],{"trials":2479,"activeCount":83},[],{"trials":2481,"activeCount":83},[],{"trials":2483,"activeCount":83},[2484],{"nctId":345,"briefTitle":346,"status":91,"phases":2485,"completion":348,"start":349,"enrollment":350,"conditions":2486,"interventions":2487},[74],[18],[39,353,198,284,218,322],{"trials":2489,"activeCount":83},[],{"trials":2491,"activeCount":83},[],{"intervention":2104,"totalTrials":112,"cells":2493},{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2500,"PHASE4":2506,"NA":2508},{"trials":2495,"activeCount":83},[],{"trials":2497,"activeCount":83},[],{"trials":2499,"activeCount":83},[],{"trials":2501,"activeCount":83},[2502],{"nctId":2095,"briefTitle":2096,"status":91,"phases":2503,"primaryCompletion":2098,"start":2099,"enrollment":2100,"conditions":2504,"interventions":2505},[74],[33,2102],[2104,1502],{"trials":2507,"activeCount":83},[],{"trials":2509,"activeCount":83},[],{"intervention":2259,"totalTrials":112,"cells":2511},{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2518,"PHASE4":2524,"NA":2526},{"trials":2513,"activeCount":83},[],{"trials":2515,"activeCount":83},[],{"trials":2517,"activeCount":83},[],{"trials":2519,"activeCount":83},[2520],{"nctId":2252,"briefTitle":2253,"status":91,"phases":2521,"primaryCompletion":2255,"start":2256,"conditions":2522,"interventions":2523},[74],[27],[2259,2260,2231,2261,1385],{"trials":2525,"activeCount":83},[],{"trials":2527,"activeCount":83},[],{"intervention":2260,"totalTrials":112,"cells":2529},{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2534,"PHASE3":2536,"PHASE4":2542,"NA":2544},{"trials":2531,"activeCount":83},[],{"trials":2533,"activeCount":83},[],{"trials":2535,"activeCount":83},[],{"trials":2537,"activeCount":83},[2538],{"nctId":2252,"briefTitle":2253,"status":91,"phases":2539,"primaryCompletion":2255,"start":2256,"conditions":2540,"interventions":2541},[74],[27],[2259,2260,2231,2261,1385],{"trials":2543,"activeCount":83},[],{"trials":2545,"activeCount":83},[],{"intervention":2261,"totalTrials":112,"cells":2547},{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2552,"PHASE3":2554,"PHASE4":2560,"NA":2562},{"trials":2549,"activeCount":83},[],{"trials":2551,"activeCount":83},[],{"trials":2553,"activeCount":83},[],{"trials":2555,"activeCount":83},[2556],{"nctId":2252,"briefTitle":2253,"status":91,"phases":2557,"primaryCompletion":2255,"start":2256,"conditions":2558,"interventions":2559},[74],[27],[2259,2260,2231,2261,1385],{"trials":2561,"activeCount":83},[],{"trials":2563,"activeCount":83},[],{"intervention":2565,"totalTrials":112,"cells":2566},"methylphenidate hydrochloride",{"EARLY_PHASE1":2567,"PHASE1":2569,"PHASE2":2571,"PHASE3":2573,"PHASE4":2583,"NA":2585},{"trials":2568,"activeCount":83},[],{"trials":2570,"activeCount":83},[],{"trials":2572,"activeCount":83},[],{"trials":2574,"activeCount":83},[2575],{"nctId":2576,"briefTitle":2577,"status":91,"phases":2578,"primaryCompletion":818,"start":2579,"enrollment":771,"conditions":2580,"interventions":2582},"NCT00003266","Methylphenidate in Treating Patients With Melanoma",[74],"1999-10-12",[539,2581],"Unspecified Adult Solid Tumor, Protocol Specific",[2565],{"trials":2584,"activeCount":83},[],{"trials":2586,"activeCount":83},[],{"intervention":2588,"totalTrials":112,"cells":2589},"GM-CSF priming",{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2594,"PHASE3":2596,"PHASE4":2608,"NA":2610},{"trials":2591,"activeCount":83},[],{"trials":2593,"activeCount":83},[],{"trials":2595,"activeCount":83},[],{"trials":2597,"activeCount":83},[2598],{"nctId":2599,"briefTitle":2600,"status":91,"phases":2601,"primaryCompletion":2602,"completion":2602,"start":2603,"enrollment":2604,"conditions":2605,"interventions":2607},"NCT04446052","Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia",[74],"2002-07-10","1993-05-21",362,[2606],"Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia",[2588],{"trials":2609,"activeCount":83},[],{"trials":2611,"activeCount":83},[],{"intervention":1204,"totalTrials":112,"cells":2613},{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2620,"PHASE4":2626,"NA":2628},{"trials":2615,"activeCount":83},[],{"trials":2617,"activeCount":83},[],{"trials":2619,"activeCount":83},[],{"trials":2621,"activeCount":83},[2622],{"nctId":1196,"briefTitle":1197,"status":91,"phases":2623,"primaryCompletion":93,"completion":1199,"start":1200,"enrollment":1201,"conditions":2624,"interventions":2625},[74],[538,501],[1204,1205],{"trials":2627,"activeCount":83},[],{"trials":2629,"activeCount":83},[],{"intervention":364,"totalTrials":112,"cells":2631},{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2638,"PHASE4":2644,"NA":2646},{"trials":2633,"activeCount":83},[],{"trials":2635,"activeCount":83},[],{"trials":2637,"activeCount":83},[],{"trials":2639,"activeCount":83},[2640],{"nctId":355,"briefTitle":356,"status":91,"phases":2641,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":2642,"interventions":2643},[74],[18],[244,364,365,366,246,367,368,245,54],{"trials":2645,"activeCount":83},[],{"trials":2647,"activeCount":83},[],{"intervention":367,"totalTrials":112,"cells":2649},{"EARLY_PHASE1":2650,"PHASE1":2652,"PHASE2":2654,"PHASE3":2656,"PHASE4":2662,"NA":2664},{"trials":2651,"activeCount":83},[],{"trials":2653,"activeCount":83},[],{"trials":2655,"activeCount":83},[],{"trials":2657,"activeCount":83},[2658],{"nctId":355,"briefTitle":356,"status":91,"phases":2659,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":2660,"interventions":2661},[74],[18],[244,364,365,366,246,367,368,245,54],{"trials":2663,"activeCount":83},[],{"trials":2665,"activeCount":83},[],{"intervention":484,"totalTrials":112,"cells":2667},{"EARLY_PHASE1":2668,"PHASE1":2670,"PHASE2":2672,"PHASE3":2674,"PHASE4":2680,"NA":2682},{"trials":2669,"activeCount":83},[],{"trials":2671,"activeCount":83},[],{"trials":2673,"activeCount":83},[],{"trials":2675,"activeCount":83},[2676],{"nctId":475,"briefTitle":476,"status":91,"phases":2677,"primaryCompletion":327,"start":478,"enrollment":479,"conditions":2678,"interventions":2679},[74],[15],[229,482,379,269,285,483,484],{"trials":2681,"activeCount":83},[],{"trials":2683,"activeCount":83},[],{"intervention":380,"totalTrials":112,"cells":2685},{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2690,"PHASE3":2692,"PHASE4":2698,"NA":2700},{"trials":2687,"activeCount":83},[],{"trials":2689,"activeCount":83},[],{"trials":2691,"activeCount":83},[],{"trials":2693,"activeCount":83},[2694],{"nctId":370,"briefTitle":371,"status":91,"phases":2695,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":2696,"interventions":2697},[74],[15],[268,379,198,269,270,380],{"trials":2699,"activeCount":83},[],{"trials":2701,"activeCount":83},[],{"intervention":390,"totalTrials":112,"cells":2703},{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2710,"PHASE4":2716,"NA":2718},{"trials":2705,"activeCount":83},[],{"trials":2707,"activeCount":83},[],{"trials":2709,"activeCount":83},[],{"trials":2711,"activeCount":83},[2712],{"nctId":382,"briefTitle":383,"status":91,"phases":2713,"primaryCompletion":385,"start":386,"enrollment":387,"conditions":2714,"interventions":2715},[74],[18],[229,39,390,198,285],{"trials":2717,"activeCount":83},[],{"trials":2719,"activeCount":83},[],{"intervention":1223,"totalTrials":112,"cells":2721},{"EARLY_PHASE1":2722,"PHASE1":2724,"PHASE2":2726,"PHASE3":2728,"PHASE4":2734,"NA":2736},{"trials":2723,"activeCount":83},[],{"trials":2725,"activeCount":83},[],{"trials":2727,"activeCount":83},[],{"trials":2729,"activeCount":83},[2730],{"nctId":1215,"briefTitle":1216,"status":91,"phases":2731,"primaryCompletion":1218,"start":1219,"enrollment":1220,"conditions":2732,"interventions":2733},[74],[30],[1223,229,482,332,1224,995],{"trials":2735,"activeCount":83},[],{"trials":2737,"activeCount":83},[],{"intervention":2739,"totalTrials":112,"cells":2740},"recombinant flt3 ligand",{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2747,"PHASE4":2756,"NA":2758},{"trials":2742,"activeCount":83},[],{"trials":2744,"activeCount":83},[],{"trials":2746,"activeCount":83},[],{"trials":2748,"activeCount":83},[2749],{"nctId":2750,"briefTitle":2751,"status":91,"phases":2752,"completion":411,"start":2753,"conditions":2754,"interventions":2755},"NCT00006223","flt3L in Treating Patients With Acute Myeloid Leukemia",[74],"2000-07",[15],[2739],{"trials":2757,"activeCount":83},[],{"trials":2759,"activeCount":83},[],{"intervention":1688,"totalTrials":112,"cells":2761},{"EARLY_PHASE1":2762,"PHASE1":2764,"PHASE2":2766,"PHASE3":2768,"PHASE4":2774,"NA":2776},{"trials":2763,"activeCount":83},[],{"trials":2765,"activeCount":83},[],{"trials":2767,"activeCount":83},[],{"trials":2769,"activeCount":83},[2770],{"nctId":1681,"briefTitle":1682,"status":91,"phases":2771,"primaryCompletion":1684,"start":1685,"conditions":2772,"interventions":2773},[74],[872],[482,1688],{"trials":2775,"activeCount":83},[],{"trials":2777,"activeCount":83},[],{"intervention":2779,"totalTrials":112,"cells":2780},"13-cis retinoic acid",{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2785,"PHASE3":2787,"PHASE4":2800,"NA":2802},{"trials":2782,"activeCount":83},[],{"trials":2784,"activeCount":83},[],{"trials":2786,"activeCount":83},[],{"trials":2788,"activeCount":83},[2789],{"nctId":2790,"briefTitle":2791,"status":91,"phases":2792,"primaryCompletion":2793,"completion":2794,"start":2795,"enrollment":2796,"conditions":2797,"interventions":2799},"NCT03370367","Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer",[74],"1999-01-15","2015-04-14","1989-05-15",189,[2798],"Stage I-II Head and Neck Cancer",[2779],{"trials":2801,"activeCount":83},[],{"trials":2803,"activeCount":83},[],{"intervention":1023,"totalTrials":112,"cells":2805},{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2810,"PHASE3":2812,"PHASE4":2818,"NA":2820},{"trials":2807,"activeCount":83},[],{"trials":2809,"activeCount":83},[],{"trials":2811,"activeCount":83},[],{"trials":2813,"activeCount":83},[2814],{"nctId":1015,"briefTitle":1016,"status":91,"phases":2815,"primaryCompletion":1018,"completion":961,"start":1019,"enrollment":1020,"conditions":2816,"interventions":2817},[74],[964,966],[283,332,284,320,426,1023],{"trials":2819,"activeCount":83},[],{"trials":2821,"activeCount":83},[],{"intervention":400,"totalTrials":112,"cells":2823},{"EARLY_PHASE1":2824,"PHASE1":2826,"PHASE2":2828,"PHASE3":2830,"PHASE4":2836,"NA":2838},{"trials":2825,"activeCount":83},[],{"trials":2827,"activeCount":83},[],{"trials":2829,"activeCount":83},[],{"trials":2831,"activeCount":83},[2832],{"nctId":392,"briefTitle":393,"status":91,"phases":2833,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":2834,"interventions":2835},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"trials":2837,"activeCount":83},[],{"trials":2839,"activeCount":83},[],{"intervention":403,"totalTrials":112,"cells":2841},{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2854,"NA":2856},{"trials":2843,"activeCount":83},[],{"trials":2845,"activeCount":83},[],{"trials":2847,"activeCount":83},[],{"trials":2849,"activeCount":83},[2850],{"nctId":392,"briefTitle":393,"status":91,"phases":2851,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":2852,"interventions":2853},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"trials":2855,"activeCount":83},[],{"trials":2857,"activeCount":83},[],{"intervention":405,"totalTrials":112,"cells":2859},{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2864,"PHASE3":2866,"PHASE4":2872,"NA":2874},{"trials":2861,"activeCount":83},[],{"trials":2863,"activeCount":83},[],{"trials":2865,"activeCount":83},[],{"trials":2867,"activeCount":83},[2868],{"nctId":392,"briefTitle":393,"status":91,"phases":2869,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":2870,"interventions":2871},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"trials":2873,"activeCount":83},[],{"trials":2875,"activeCount":83},[],{"intervention":406,"totalTrials":112,"cells":2877},{"EARLY_PHASE1":2878,"PHASE1":2880,"PHASE2":2882,"PHASE3":2884,"PHASE4":2890,"NA":2892},{"trials":2879,"activeCount":83},[],{"trials":2881,"activeCount":83},[],{"trials":2883,"activeCount":83},[],{"trials":2885,"activeCount":83},[2886],{"nctId":392,"briefTitle":393,"status":91,"phases":2887,"primaryCompletion":395,"start":396,"enrollment":397,"conditions":2888,"interventions":2889},[74],[15],[268,400,198,269,401,402,285,403,404,405,320,218,406,322],{"trials":2891,"activeCount":83},[],{"trials":2893,"activeCount":83},[],{"intervention":2895,"totalTrials":112,"cells":2896},"marimastat",{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2901,"PHASE3":2903,"PHASE4":2913,"NA":2915},{"trials":2898,"activeCount":83},[],{"trials":2900,"activeCount":83},[],{"trials":2902,"activeCount":83},[],{"trials":2904,"activeCount":83},[2905],{"nctId":2906,"briefTitle":2907,"status":91,"phases":2908,"primaryCompletion":224,"start":2909,"enrollment":2910,"conditions":2911,"interventions":2912},"NCT00003010","Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy",[74],"1997-12-02",334,[20],[2895],{"trials":2914,"activeCount":83},[],{"trials":2916,"activeCount":83},[],{"intervention":2918,"totalTrials":112,"cells":2919},"conjugated estrogens",{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2939,"NA":2941},{"trials":2921,"activeCount":83},[],{"trials":2923,"activeCount":83},[],{"trials":2925,"activeCount":83},[],{"trials":2927,"activeCount":83},[2928],{"nctId":2929,"briefTitle":2930,"status":91,"phases":2931,"primaryCompletion":2932,"completion":961,"start":2933,"conditions":2934,"interventions":2937},"NCT00026286","Hormone Replacement Therapy for Hot Flashes and\u002For Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer",[74],"2002-08","2000-11-28",[20,2935,2936],"Hot Flashes","Menopausal Symptoms",[2918,2938],"medroxyprogesterone",{"trials":2940,"activeCount":83},[],{"trials":2942,"activeCount":83},[],{"intervention":2938,"totalTrials":112,"cells":2944},{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2951,"PHASE4":2957,"NA":2959},{"trials":2946,"activeCount":83},[],{"trials":2948,"activeCount":83},[],{"trials":2950,"activeCount":83},[],{"trials":2952,"activeCount":83},[2953],{"nctId":2929,"briefTitle":2930,"status":91,"phases":2954,"primaryCompletion":2932,"completion":961,"start":2933,"conditions":2955,"interventions":2956},[74],[20,2935,2936],[2918,2938],{"trials":2958,"activeCount":83},[],{"trials":2960,"activeCount":83},[],{"intervention":503,"totalTrials":112,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2969,"PHASE4":2975,"NA":2977},{"trials":2964,"activeCount":83},[],{"trials":2966,"activeCount":83},[],{"trials":2968,"activeCount":83},[],{"trials":2970,"activeCount":83},[2971],{"nctId":494,"briefTitle":495,"status":91,"phases":2972,"primaryCompletion":497,"start":498,"enrollment":499,"conditions":2973,"interventions":2974},[74],[15,501],[229,268,269,401,503],{"trials":2976,"activeCount":83},[],{"trials":2978,"activeCount":83},[],{"intervention":2980,"totalTrials":112,"cells":2981},"bleomycin sulfate",{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2988,"PHASE4":2999,"NA":3001},{"trials":2983,"activeCount":83},[],{"trials":2985,"activeCount":83},[],{"trials":2987,"activeCount":83},[],{"trials":2989,"activeCount":83},[2990],{"nctId":2991,"briefTitle":2992,"status":91,"phases":2993,"primaryCompletion":960,"start":2994,"enrollment":2995,"conditions":2996,"interventions":2997},"NCT00002872","Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions",[74],"1997-01-10",480,[98],[2980,2998],"doxycycline",{"trials":3000,"activeCount":83},[],{"trials":3002,"activeCount":83},[],{"intervention":2998,"totalTrials":112,"cells":3004},{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3011,"PHASE4":3017,"NA":3019},{"trials":3006,"activeCount":83},[],{"trials":3008,"activeCount":83},[],{"trials":3010,"activeCount":83},[],{"trials":3012,"activeCount":83},[3013],{"nctId":2991,"briefTitle":2992,"status":91,"phases":3014,"primaryCompletion":960,"start":2994,"enrollment":2995,"conditions":3015,"interventions":3016},[74],[98],[2980,2998],{"trials":3018,"activeCount":83},[],{"trials":3020,"activeCount":83},[],{"intervention":1384,"totalTrials":112,"cells":3022},{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3029,"PHASE4":3035,"NA":3037},{"trials":3024,"activeCount":83},[],{"trials":3026,"activeCount":83},[],{"trials":3028,"activeCount":83},[],{"trials":3030,"activeCount":83},[3031],{"nctId":1378,"briefTitle":1379,"status":91,"phases":3032,"primaryCompletion":224,"start":1381,"conditions":3033,"interventions":3034},[74],[27],[416,850,1384,1385],{"trials":3036,"activeCount":83},[],{"trials":3038,"activeCount":83},[],{"intervention":898,"totalTrials":1433,"cells":3040},{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3042,"activeCount":83},[],{"trials":3044,"activeCount":83},[],{"trials":3046,"activeCount":83},[3047,3051,3062,3066,3070,3074],{"nctId":1766,"briefTitle":1767,"status":91,"phases":3048,"completion":348,"start":1769,"conditions":3049,"interventions":3050},[73],[33],[216,1013,898,404],{"nctId":3052,"briefTitle":3053,"status":91,"phases":3054,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":3059,"interventions":3060},"NCT01079780","Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy",[73],"2021-02-22","2021-08-17","2011-01-18",136,[33],[917,3061,898],"ramucirumab",{"nctId":1347,"briefTitle":1348,"status":91,"phases":3063,"primaryCompletion":497,"completion":1350,"start":1351,"enrollment":1352,"conditions":3064,"interventions":3065},[73],[1191],[917,416,898],{"nctId":887,"briefTitle":888,"status":91,"phases":3067,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":3068,"interventions":3069},[73],[895,896],[332,898,426],{"nctId":1360,"briefTitle":1361,"status":91,"phases":3071,"primaryCompletion":903,"completion":1363,"start":1364,"conditions":3072,"interventions":3073},[73],[25],[416,898],{"nctId":1773,"briefTitle":1774,"status":91,"phases":3075,"primaryCompletion":1776,"completion":1777,"start":1778,"enrollment":1779,"conditions":3076,"interventions":3077},[73],[33],[216,1013,898,404,1336],{"trials":3079,"activeCount":83},[],{"trials":3081,"activeCount":83},[],{"trials":3083,"activeCount":83},[],{"intervention":297,"totalTrials":2038,"cells":3085},{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3090,"PHASE3":3107,"PHASE4":3109,"NA":3111},{"trials":3087,"activeCount":83},[],{"trials":3089,"activeCount":83},[],{"trials":3091,"activeCount":83},[3092,3096,3100],{"nctId":1399,"briefTitle":1400,"status":91,"phases":3093,"primaryCompletion":1331,"completion":1402,"start":1403,"enrollment":1404,"conditions":3094,"interventions":3095},[73],[15,501,1406],[1408,310,1409,1410,1411],{"nctId":288,"briefTitle":289,"status":91,"phases":3097,"primaryCompletion":291,"completion":292,"start":293,"conditions":3098,"interventions":3099},[73],[295],[268,198,297,298,299],{"nctId":3101,"briefTitle":3102,"status":237,"phases":3103,"primaryCompletion":373,"completion":798,"start":3104,"enrollment":2007,"conditions":3105,"interventions":3106},"NCT00070291","Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma",[73],"2006-01-24",[18],[297],{"trials":3108,"activeCount":83},[],{"trials":3110,"activeCount":83},[],{"trials":3112,"activeCount":83},[],{"intervention":1411,"totalTrials":2038,"cells":3114},{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3133,"PHASE4":3135,"NA":3137},{"trials":3116,"activeCount":83},[],{"trials":3118,"activeCount":83},[],{"trials":3120,"activeCount":83},[3121,3125,3129],{"nctId":1399,"briefTitle":1400,"status":91,"phases":3122,"primaryCompletion":1331,"completion":1402,"start":1403,"enrollment":1404,"conditions":3123,"interventions":3124},[73],[15,501,1406],[1408,310,1409,1410,1411],{"nctId":248,"briefTitle":249,"status":91,"phases":3126,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":3127,"interventions":3128},[73],[15],[39,198,257,258],{"nctId":1428,"briefTitle":1429,"status":237,"phases":3130,"primaryCompletion":1431,"completion":798,"start":1432,"enrollment":1433,"conditions":3131,"interventions":3132},[73],[18],[1411,1436,1437,310],{"trials":3134,"activeCount":83},[],{"trials":3136,"activeCount":83},[],{"trials":3138,"activeCount":83},[],{"intervention":299,"totalTrials":2038,"cells":3140},{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3149,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3142,"activeCount":83},[],{"trials":3144,"activeCount":83},[3145],{"nctId":1142,"briefTitle":1143,"status":237,"phases":3146,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":433,"conditions":3147,"interventions":3148},[72],[1149,295],[229,1151,299],{"trials":3150,"activeCount":83},[3151,3155],{"nctId":288,"briefTitle":289,"status":91,"phases":3152,"primaryCompletion":291,"completion":292,"start":293,"conditions":3153,"interventions":3154},[73],[295],[268,198,297,298,299],{"nctId":1178,"briefTitle":1179,"status":91,"phases":3156,"primaryCompletion":1181,"start":1182,"conditions":3157,"interventions":3158},[73],[295],[229,299],{"trials":3160,"activeCount":83},[],{"trials":3162,"activeCount":83},[],{"trials":3164,"activeCount":83},[],{"intervention":1549,"totalTrials":79,"cells":3166},{"EARLY_PHASE1":3167,"PHASE1":3169,"PHASE2":3171,"PHASE3":3181,"PHASE4":3183,"NA":3185},{"trials":3168,"activeCount":83},[],{"trials":3170,"activeCount":83},[],{"trials":3172,"activeCount":83},[3173,3177],{"nctId":1540,"briefTitle":1541,"status":91,"phases":3174,"primaryCompletion":1543,"completion":240,"start":1544,"enrollment":1545,"conditions":3175,"interventions":3176},[73],[1547],[1549,919,368,1550,1551],{"nctId":1951,"briefTitle":1952,"status":91,"phases":3178,"primaryCompletion":497,"completion":798,"start":1954,"enrollment":1955,"conditions":3179,"interventions":3180},[73],[1957,1958],[244,1960,1549,1961],{"trials":3182,"activeCount":83},[],{"trials":3184,"activeCount":83},[],{"trials":3186,"activeCount":83},[],{"intervention":1059,"totalTrials":79,"cells":3188},{"EARLY_PHASE1":3189,"PHASE1":3191,"PHASE2":3193,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3190,"activeCount":83},[],{"trials":3192,"activeCount":83},[],{"trials":3194,"activeCount":83},[3195,3199],{"nctId":1052,"briefTitle":1053,"status":91,"phases":3196,"primaryCompletion":890,"completion":798,"start":1055,"enrollment":820,"conditions":3197,"interventions":3198},[73],[1057],[1059,813,283],{"nctId":1271,"briefTitle":1272,"status":91,"phases":3200,"primaryCompletion":1145,"completion":925,"start":1274,"enrollment":213,"conditions":3201,"interventions":3202},[73],[964,965,966],[813,1059],{"trials":3204,"activeCount":83},[],{"trials":3206,"activeCount":83},[],{"trials":3208,"activeCount":83},[],{"intervention":228,"totalTrials":79,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3225,"PHASE4":3227,"NA":3229},{"trials":3212,"activeCount":83},[],{"trials":3214,"activeCount":83},[],{"trials":3216,"activeCount":83},[3217,3221],{"nctId":221,"briefTitle":222,"status":91,"phases":3218,"primaryCompletion":224,"start":225,"conditions":3219,"interventions":3220},[73],[15],[228,229,198],{"nctId":248,"briefTitle":249,"status":91,"phases":3222,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":3223,"interventions":3224},[73],[15],[39,198,257,258],{"trials":3226,"activeCount":83},[],{"trials":3228,"activeCount":83},[],{"trials":3230,"activeCount":83},[],{"intervention":1087,"totalTrials":79,"cells":3232},{"EARLY_PHASE1":3233,"PHASE1":3235,"PHASE2":3237,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3234,"activeCount":83},[],{"trials":3236,"activeCount":83},[],{"trials":3238,"activeCount":83},[3239,3243],{"nctId":1081,"briefTitle":1082,"status":1083,"phases":3240,"start":264,"enrollment":83,"conditions":3241,"interventions":3242},[73],[23],[216,283,1087,813],{"nctId":3244,"briefTitle":3245,"status":1083,"phases":3246,"primaryCompletion":3247,"start":3248,"enrollment":83,"conditions":3249,"interventions":3250},"NCT00685633","Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer",[73],"2010-06","2008-12",[27],[2247,1087],{"trials":3252,"activeCount":83},[],{"trials":3254,"activeCount":83},[],{"trials":3256,"activeCount":83},[],{"intervention":1653,"totalTrials":79,"cells":3258},{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3263,"PHASE3":3273,"PHASE4":3275,"NA":3277},{"trials":3260,"activeCount":83},[],{"trials":3262,"activeCount":83},[],{"trials":3264,"activeCount":83},[3265,3269],{"nctId":1645,"briefTitle":1646,"status":91,"phases":3266,"primaryCompletion":1535,"start":1648,"conditions":3267,"interventions":3268},[73],[30],[1651,1652,1653,482,268,1654],{"nctId":1715,"briefTitle":1716,"status":91,"phases":3270,"primaryCompletion":1718,"completion":1719,"start":1720,"enrollment":1721,"conditions":3271,"interventions":3272},[73],[30],[1653,1724,1725,268,1726],{"trials":3274,"activeCount":83},[],{"trials":3276,"activeCount":83},[],{"trials":3278,"activeCount":83},[],{"intervention":2247,"totalTrials":79,"cells":3280},{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3285,"PHASE3":3295,"PHASE4":3297,"NA":3299},{"trials":3282,"activeCount":83},[],{"trials":3284,"activeCount":83},[],{"trials":3286,"activeCount":83},[3287,3291],{"nctId":2240,"briefTitle":2241,"status":1083,"phases":3288,"start":2243,"enrollment":83,"conditions":3289,"interventions":3290},[73],[27],[2246,2247,2248,2231],{"nctId":3244,"briefTitle":3245,"status":1083,"phases":3292,"primaryCompletion":3247,"start":3248,"enrollment":83,"conditions":3293,"interventions":3294},[73],[27],[2247,1087],{"trials":3296,"activeCount":83},[],{"trials":3298,"activeCount":83},[],{"trials":3300,"activeCount":83},[],{"intervention":3302,"totalTrials":79,"cells":3303},"recombinant interleukin-12",{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3326,"PHASE4":3328,"NA":3330},{"trials":3305,"activeCount":83},[],{"trials":3307,"activeCount":83},[],{"trials":3309,"activeCount":83},[3310,3319],{"nctId":3311,"briefTitle":3312,"status":91,"phases":3313,"completion":3314,"start":3315,"conditions":3316,"interventions":3318},"NCT00003017","Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix",[73],"2005-08","1997-07",[3317],"Cervical Cancer",[3302],{"nctId":3320,"briefTitle":3321,"status":91,"phases":3322,"completion":348,"start":349,"enrollment":3323,"conditions":3324,"interventions":3325},"NCT00003149","Interleukin-12 in Treating Patients With Multiple Myeloma",[73],40,[295],[3302],{"trials":3327,"activeCount":83},[],{"trials":3329,"activeCount":83},[],{"trials":3331,"activeCount":83},[],{"intervention":2055,"totalTrials":112,"cells":3333},{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3338,"PHASE3":3344,"PHASE4":3346,"NA":3348},{"trials":3335,"activeCount":83},[],{"trials":3337,"activeCount":83},[],{"trials":3339,"activeCount":83},[3340],{"nctId":2047,"briefTitle":2048,"status":1083,"phases":3341,"enrollment":83,"conditions":3342,"interventions":3343},[73],[2051,2052,2053],[2055,298,2056],{"trials":3345,"activeCount":83},[],{"trials":3347,"activeCount":83},[],{"trials":3349,"activeCount":83},[],{"intervention":2056,"totalTrials":112,"cells":3351},{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3353,"activeCount":83},[],{"trials":3355,"activeCount":83},[],{"trials":3357,"activeCount":83},[3358],{"nctId":2047,"briefTitle":2048,"status":1083,"phases":3359,"enrollment":83,"conditions":3360,"interventions":3361},[73],[2051,2052,2053],[2055,298,2056],{"trials":3363,"activeCount":83},[],{"trials":3365,"activeCount":83},[],{"trials":3367,"activeCount":83},[],{"intervention":3369,"totalTrials":112,"cells":3370},"ISIS 3521",{"EARLY_PHASE1":3371,"PHASE1":3373,"PHASE2":3375,"PHASE3":3386,"PHASE4":3388,"NA":3390},{"trials":3372,"activeCount":83},[],{"trials":3374,"activeCount":83},[],{"trials":3376,"activeCount":83},[3377],{"nctId":3378,"briefTitle":3379,"status":91,"phases":3380,"primaryCompletion":3381,"start":3382,"conditions":3383,"interventions":3384},"NCT00003236","Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer",[73],"2002-06","1998-07-13",[20],[3369,3385],"ISIS 5132",{"trials":3387,"activeCount":83},[],{"trials":3389,"activeCount":83},[],{"trials":3391,"activeCount":83},[],{"intervention":3385,"totalTrials":112,"cells":3393},{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3395,"activeCount":83},[],{"trials":3397,"activeCount":83},[],{"trials":3399,"activeCount":83},[3400],{"nctId":3378,"briefTitle":3379,"status":91,"phases":3401,"primaryCompletion":3381,"start":3382,"conditions":3402,"interventions":3403},[73],[20],[3369,3385],{"trials":3405,"activeCount":83},[],{"trials":3407,"activeCount":83},[],{"trials":3409,"activeCount":83},[],{"intervention":2087,"totalTrials":112,"cells":3411},{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3416,"PHASE3":3422,"PHASE4":3424,"NA":3426},{"trials":3413,"activeCount":83},[],{"trials":3415,"activeCount":83},[],{"trials":3417,"activeCount":83},[3418],{"nctId":2080,"briefTitle":2081,"status":1083,"phases":3419,"enrollment":83,"conditions":3420,"interventions":3421},[73],[2084,2085],[1502,2087],{"trials":3423,"activeCount":83},[],{"trials":3425,"activeCount":83},[],{"trials":3427,"activeCount":83},[],{"intervention":1550,"totalTrials":112,"cells":3429},{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3440,"PHASE4":3442,"NA":3444},{"trials":3431,"activeCount":83},[],{"trials":3433,"activeCount":83},[],{"trials":3435,"activeCount":83},[3436],{"nctId":1540,"briefTitle":1541,"status":91,"phases":3437,"primaryCompletion":1543,"completion":240,"start":1544,"enrollment":1545,"conditions":3438,"interventions":3439},[73],[1547],[1549,919,368,1550,1551],{"trials":3441,"activeCount":83},[],{"trials":3443,"activeCount":83},[],{"trials":3445,"activeCount":83},[],{"intervention":1551,"totalTrials":112,"cells":3447},{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3458,"PHASE4":3460,"NA":3462},{"trials":3449,"activeCount":83},[],{"trials":3451,"activeCount":83},[],{"trials":3453,"activeCount":83},[3454],{"nctId":1540,"briefTitle":1541,"status":91,"phases":3455,"primaryCompletion":1543,"completion":240,"start":1544,"enrollment":1545,"conditions":3456,"interventions":3457},[73],[1547],[1549,919,368,1550,1551],{"trials":3459,"activeCount":83},[],{"trials":3461,"activeCount":83},[],{"trials":3463,"activeCount":83},[],{"intervention":1335,"totalTrials":112,"cells":3465},{"EARLY_PHASE1":3466,"PHASE1":3468,"PHASE2":3470,"PHASE3":3476,"PHASE4":3478,"NA":3480},{"trials":3467,"activeCount":83},[],{"trials":3469,"activeCount":83},[],{"trials":3471,"activeCount":83},[3472],{"nctId":1327,"briefTitle":1328,"status":237,"phases":3473,"primaryCompletion":1330,"completion":1331,"start":1332,"enrollment":870,"conditions":3474,"interventions":3475},[73],[895],[1335,1336,954,1337],{"trials":3477,"activeCount":83},[],{"trials":3479,"activeCount":83},[],{"trials":3481,"activeCount":83},[],{"intervention":803,"totalTrials":112,"cells":3483},{"EARLY_PHASE1":3484,"PHASE1":3486,"PHASE2":3488,"PHASE3":3494,"PHASE4":3496,"NA":3498},{"trials":3485,"activeCount":83},[],{"trials":3487,"activeCount":83},[],{"trials":3489,"activeCount":83},[3490],{"nctId":795,"briefTitle":796,"status":91,"phases":3491,"primaryCompletion":798,"completion":240,"start":799,"enrollment":800,"conditions":3492,"interventions":3493},[73],[23],[803,804,426],{"trials":3495,"activeCount":83},[],{"trials":3497,"activeCount":83},[],{"trials":3499,"activeCount":83},[],{"intervention":804,"totalTrials":112,"cells":3501},{"EARLY_PHASE1":3502,"PHASE1":3504,"PHASE2":3506,"PHASE3":3512,"PHASE4":3514,"NA":3516},{"trials":3503,"activeCount":83},[],{"trials":3505,"activeCount":83},[],{"trials":3507,"activeCount":83},[3508],{"nctId":795,"briefTitle":796,"status":91,"phases":3509,"primaryCompletion":798,"completion":240,"start":799,"enrollment":800,"conditions":3510,"interventions":3511},[73],[23],[803,804,426],{"trials":3513,"activeCount":83},[],{"trials":3515,"activeCount":83},[],{"trials":3517,"activeCount":83},[],{"intervention":3519,"totalTrials":112,"cells":3520},"dasatinib",{"EARLY_PHASE1":3521,"PHASE1":3523,"PHASE2":3525,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3522,"activeCount":83},[],{"trials":3524,"activeCount":83},[],{"trials":3526,"activeCount":83},[3527],{"nctId":3528,"briefTitle":3529,"status":91,"phases":3530,"primaryCompletion":3531,"completion":3532,"start":3533,"enrollment":3534,"conditions":3535,"interventions":3536},"NCT00700882","Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",[73],"2016-05-06","2020-12-28","2009-07-02",81,[30],[3519],{"trials":3538,"activeCount":83},[],{"trials":3540,"activeCount":83},[],{"trials":3542,"activeCount":83},[],{"intervention":3544,"totalTrials":112,"cells":3545},"perifosine",{"EARLY_PHASE1":3546,"PHASE1":3548,"PHASE2":3550,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3547,"activeCount":83},[],{"trials":3549,"activeCount":83},[],{"trials":3551,"activeCount":83},[3552],{"nctId":3553,"briefTitle":3554,"status":91,"phases":3555,"completion":3314,"start":3556,"conditions":3557,"interventions":3558},"NCT00059982","Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer",[73],"2003-07",[1191],[3544],{"trials":3560,"activeCount":83},[],{"trials":3562,"activeCount":83},[],{"trials":3564,"activeCount":83},[],{"intervention":2305,"totalTrials":112,"cells":3566},{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3571,"PHASE3":3577,"PHASE4":3579,"NA":3581},{"trials":3568,"activeCount":83},[],{"trials":3570,"activeCount":83},[],{"trials":3572,"activeCount":83},[3573],{"nctId":2298,"briefTitle":2299,"status":91,"phases":3574,"primaryCompletion":2301,"completion":1033,"start":2302,"enrollment":317,"conditions":3575,"interventions":3576},[73],[30],[2289,2305],{"trials":3578,"activeCount":83},[],{"trials":3580,"activeCount":83},[],{"trials":3582,"activeCount":83},[],{"intervention":1409,"totalTrials":112,"cells":3584},{"EARLY_PHASE1":3585,"PHASE1":3587,"PHASE2":3589,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3586,"activeCount":83},[],{"trials":3588,"activeCount":83},[],{"trials":3590,"activeCount":83},[3591],{"nctId":1399,"briefTitle":1400,"status":91,"phases":3592,"primaryCompletion":1331,"completion":1402,"start":1403,"enrollment":1404,"conditions":3593,"interventions":3594},[73],[15,501,1406],[1408,310,1409,1410,1411],{"trials":3596,"activeCount":83},[],{"trials":3598,"activeCount":83},[],{"trials":3600,"activeCount":83},[],{"intervention":1410,"totalTrials":112,"cells":3602},{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3604,"activeCount":83},[],{"trials":3606,"activeCount":83},[],{"trials":3608,"activeCount":83},[3609],{"nctId":1399,"briefTitle":1400,"status":91,"phases":3610,"primaryCompletion":1331,"completion":1402,"start":1403,"enrollment":1404,"conditions":3611,"interventions":3612},[73],[15,501,1406],[1408,310,1409,1410,1411],{"trials":3614,"activeCount":83},[],{"trials":3616,"activeCount":83},[],{"trials":3618,"activeCount":83},[],{"intervention":271,"totalTrials":112,"cells":3620},{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3631,"PHASE4":3633,"NA":3635},{"trials":3622,"activeCount":83},[],{"trials":3624,"activeCount":83},[],{"trials":3626,"activeCount":83},[3627],{"nctId":260,"briefTitle":261,"status":91,"phases":3628,"primaryCompletion":263,"completion":264,"start":265,"conditions":3629,"interventions":3630},[73],[15],[268,198,269,270,271,272],{"trials":3632,"activeCount":83},[],{"trials":3634,"activeCount":83},[],{"trials":3636,"activeCount":83},[],{"intervention":272,"totalTrials":112,"cells":3638},{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3649,"PHASE4":3651,"NA":3653},{"trials":3640,"activeCount":83},[],{"trials":3642,"activeCount":83},[],{"trials":3644,"activeCount":83},[3645],{"nctId":260,"briefTitle":261,"status":91,"phases":3646,"primaryCompletion":263,"completion":264,"start":265,"conditions":3647,"interventions":3648},[73],[15],[268,198,269,270,271,272],{"trials":3650,"activeCount":83},[],{"trials":3652,"activeCount":83},[],{"trials":3654,"activeCount":83},[],{"intervention":286,"totalTrials":112,"cells":3656},{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3661,"PHASE3":3667,"PHASE4":3669,"NA":3671},{"trials":3658,"activeCount":83},[],{"trials":3660,"activeCount":83},[],{"trials":3662,"activeCount":83},[3663],{"nctId":274,"briefTitle":275,"status":91,"phases":3664,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":3665,"interventions":3666},[73],[18],[229,39,283,198,284,285,286,218,219],{"trials":3668,"activeCount":83},[],{"trials":3670,"activeCount":83},[],{"trials":3672,"activeCount":83},[],{"intervention":3674,"totalTrials":112,"cells":3675},"dalteparin",{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3690,"PHASE4":3692,"NA":3694},{"trials":3677,"activeCount":83},[],{"trials":3679,"activeCount":83},[],{"trials":3681,"activeCount":83},[3682],{"nctId":3683,"briefTitle":3684,"status":91,"phases":3685,"primaryCompletion":1306,"completion":264,"start":3686,"enrollment":3687,"conditions":3688,"interventions":3689},"NCT00028678","Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme",[73],"2002-07-11",45,[109],[3674],{"trials":3691,"activeCount":83},[],{"trials":3693,"activeCount":83},[],{"trials":3695,"activeCount":83},[],{"intervention":3697,"totalTrials":112,"cells":3698},"arsenic trioxide",{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3703,"PHASE3":3712,"PHASE4":3714,"NA":3716},{"trials":3700,"activeCount":83},[],{"trials":3702,"activeCount":83},[],{"trials":3704,"activeCount":83},[3705],{"nctId":3706,"briefTitle":3707,"status":91,"phases":3708,"completion":348,"start":3709,"conditions":3710,"interventions":3711},"NCT00006008","Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",[73],"2000-06",[15],[3697],{"trials":3713,"activeCount":83},[],{"trials":3715,"activeCount":83},[],{"trials":3717,"activeCount":83},[],{"intervention":3719,"totalTrials":112,"cells":3720},"theophylline",{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3734,"PHASE4":3736,"NA":3738},{"trials":3722,"activeCount":83},[],{"trials":3724,"activeCount":83},[],{"trials":3726,"activeCount":83},[3727],{"nctId":3728,"briefTitle":3729,"status":91,"phases":3730,"primaryCompletion":3731,"start":1289,"conditions":3732,"interventions":3733},"NCT00003808","Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia",[73],"2002-09",[15],[3719],{"trials":3735,"activeCount":83},[],{"trials":3737,"activeCount":83},[],{"trials":3739,"activeCount":83},[],{"intervention":3741,"totalTrials":112,"cells":3742},"therapeutic allogeneic lymphocytes",{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3747,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3744,"activeCount":83},[],{"trials":3746,"activeCount":83},[],{"trials":3748,"activeCount":83},[3749],{"nctId":3750,"briefTitle":3751,"status":91,"phases":3752,"primaryCompletion":291,"completion":1363,"start":3753,"enrollment":870,"conditions":3754,"interventions":3755},"NCT00003153","Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation",[73],"1998-07-22",[295],[3741],{"trials":3757,"activeCount":83},[],{"trials":3759,"activeCount":83},[],{"trials":3761,"activeCount":83},[],{"intervention":321,"totalTrials":112,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3768,"PHASE3":3774,"PHASE4":3776,"NA":3778},{"trials":3765,"activeCount":83},[],{"trials":3767,"activeCount":83},[],{"trials":3769,"activeCount":83},[3770],{"nctId":312,"briefTitle":313,"status":91,"phases":3771,"primaryCompletion":315,"start":316,"enrollment":317,"conditions":3772,"interventions":3773},[73],[18],[229,198,269,320,321,218,322],{"trials":3775,"activeCount":83},[],{"trials":3777,"activeCount":83},[],{"trials":3779,"activeCount":83},[],{"intervention":852,"totalTrials":112,"cells":3781},{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3792,"PHASE4":3794,"NA":3796},{"trials":3783,"activeCount":83},[],{"trials":3785,"activeCount":83},[],{"trials":3787,"activeCount":83},[3788],{"nctId":843,"briefTitle":844,"status":91,"phases":3789,"primaryCompletion":846,"start":847,"conditions":3790,"interventions":3791},[73],[27],[482,850,851,852,426,853],{"trials":3793,"activeCount":83},[],{"trials":3795,"activeCount":83},[],{"trials":3797,"activeCount":83},[],{"intervention":853,"totalTrials":112,"cells":3799},{"EARLY_PHASE1":3800,"PHASE1":3802,"PHASE2":3804,"PHASE3":3810,"PHASE4":3812,"NA":3814},{"trials":3801,"activeCount":83},[],{"trials":3803,"activeCount":83},[],{"trials":3805,"activeCount":83},[3806],{"nctId":843,"briefTitle":844,"status":91,"phases":3807,"primaryCompletion":846,"start":847,"conditions":3808,"interventions":3809},[73],[27],[482,850,851,852,426,853],{"trials":3811,"activeCount":83},[],{"trials":3813,"activeCount":83},[],{"trials":3815,"activeCount":83},[],{"intervention":1651,"totalTrials":112,"cells":3817},{"EARLY_PHASE1":3818,"PHASE1":3820,"PHASE2":3822,"PHASE3":3828,"PHASE4":3830,"NA":3832},{"trials":3819,"activeCount":83},[],{"trials":3821,"activeCount":83},[],{"trials":3823,"activeCount":83},[3824],{"nctId":1645,"briefTitle":1646,"status":91,"phases":3825,"primaryCompletion":1535,"start":1648,"conditions":3826,"interventions":3827},[73],[30],[1651,1652,1653,482,268,1654],{"trials":3829,"activeCount":83},[],{"trials":3831,"activeCount":83},[],{"trials":3833,"activeCount":83},[],{"intervention":1652,"totalTrials":112,"cells":3835},{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3846,"PHASE4":3848,"NA":3850},{"trials":3837,"activeCount":83},[],{"trials":3839,"activeCount":83},[],{"trials":3841,"activeCount":83},[3842],{"nctId":1645,"briefTitle":1646,"status":91,"phases":3843,"primaryCompletion":1535,"start":1648,"conditions":3844,"interventions":3845},[73],[30],[1651,1652,1653,482,268,1654],{"trials":3847,"activeCount":83},[],{"trials":3849,"activeCount":83},[],{"trials":3851,"activeCount":83},[],{"intervention":1654,"totalTrials":112,"cells":3853},{"EARLY_PHASE1":3854,"PHASE1":3856,"PHASE2":3858,"PHASE3":3864,"PHASE4":3866,"NA":3868},{"trials":3855,"activeCount":83},[],{"trials":3857,"activeCount":83},[],{"trials":3859,"activeCount":83},[3860],{"nctId":1645,"briefTitle":1646,"status":91,"phases":3861,"primaryCompletion":1535,"start":1648,"conditions":3862,"interventions":3863},[73],[30],[1651,1652,1653,482,268,1654],{"trials":3865,"activeCount":83},[],{"trials":3867,"activeCount":83},[],{"trials":3869,"activeCount":83},[],{"intervention":2246,"totalTrials":112,"cells":3871},{"EARLY_PHASE1":3872,"PHASE1":3874,"PHASE2":3876,"PHASE3":3882,"PHASE4":3884,"NA":3886},{"trials":3873,"activeCount":83},[],{"trials":3875,"activeCount":83},[],{"trials":3877,"activeCount":83},[3878],{"nctId":2240,"briefTitle":2241,"status":1083,"phases":3879,"start":2243,"enrollment":83,"conditions":3880,"interventions":3881},[73],[27],[2246,2247,2248,2231],{"trials":3883,"activeCount":83},[],{"trials":3885,"activeCount":83},[],{"trials":3887,"activeCount":83},[],{"intervention":2248,"totalTrials":112,"cells":3889},{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3891,"activeCount":83},[],{"trials":3893,"activeCount":83},[],{"trials":3895,"activeCount":83},[3896],{"nctId":2240,"briefTitle":2241,"status":1083,"phases":3897,"start":2243,"enrollment":83,"conditions":3898,"interventions":3899},[73],[27],[2246,2247,2248,2231],{"trials":3901,"activeCount":83},[],{"trials":3903,"activeCount":83},[],{"trials":3905,"activeCount":83},[],{"intervention":1436,"totalTrials":112,"cells":3907},{"EARLY_PHASE1":3908,"PHASE1":3910,"PHASE2":3912,"PHASE3":3918,"PHASE4":3920,"NA":3922},{"trials":3909,"activeCount":83},[],{"trials":3911,"activeCount":83},[],{"trials":3913,"activeCount":83},[3914],{"nctId":1428,"briefTitle":1429,"status":237,"phases":3915,"primaryCompletion":1431,"completion":798,"start":1432,"enrollment":1433,"conditions":3916,"interventions":3917},[73],[18],[1411,1436,1437,310],{"trials":3919,"activeCount":83},[],{"trials":3921,"activeCount":83},[],{"trials":3923,"activeCount":83},[],{"intervention":1437,"totalTrials":112,"cells":3925},{"EARLY_PHASE1":3926,"PHASE1":3928,"PHASE2":3930,"PHASE3":3936,"PHASE4":3938,"NA":3940},{"trials":3927,"activeCount":83},[],{"trials":3929,"activeCount":83},[],{"trials":3931,"activeCount":83},[3932],{"nctId":1428,"briefTitle":1429,"status":237,"phases":3933,"primaryCompletion":1431,"completion":798,"start":1432,"enrollment":1433,"conditions":3934,"interventions":3935},[73],[18],[1411,1436,1437,310],{"trials":3937,"activeCount":83},[],{"trials":3939,"activeCount":83},[],{"trials":3941,"activeCount":83},[],{"intervention":3943,"totalTrials":112,"cells":3944},"atrasentan hydrochloride",{"EARLY_PHASE1":3945,"PHASE1":3947,"PHASE2":3949,"PHASE3":3960,"PHASE4":3962,"NA":3964},{"trials":3946,"activeCount":83},[],{"trials":3948,"activeCount":83},[],{"trials":3950,"activeCount":83},[3951],{"nctId":3952,"briefTitle":3953,"status":91,"phases":3954,"primaryCompletion":3955,"start":3956,"enrollment":3957,"conditions":3958,"interventions":3959},"NCT00039429","Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer",[73],"2006-04","2003-07-14",180,[872],[3943],{"trials":3961,"activeCount":83},[],{"trials":3963,"activeCount":83},[],{"trials":3965,"activeCount":83},[],{"intervention":882,"totalTrials":112,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3978,"PHASE4":3980,"NA":3982},{"trials":3969,"activeCount":83},[],{"trials":3971,"activeCount":83},[],{"trials":3973,"activeCount":83},[3974],{"nctId":875,"briefTitle":876,"status":91,"phases":3975,"primaryCompletion":385,"start":878,"enrollment":329,"conditions":3976,"interventions":3977},[73],[880],[882,883,426,884,885],{"trials":3979,"activeCount":83},[],{"trials":3981,"activeCount":83},[],{"trials":3983,"activeCount":83},[],{"intervention":883,"totalTrials":112,"cells":3985},{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":3996,"PHASE4":3998,"NA":4000},{"trials":3987,"activeCount":83},[],{"trials":3989,"activeCount":83},[],{"trials":3991,"activeCount":83},[3992],{"nctId":875,"briefTitle":876,"status":91,"phases":3993,"primaryCompletion":385,"start":878,"enrollment":329,"conditions":3994,"interventions":3995},[73],[880],[882,883,426,884,885],{"trials":3997,"activeCount":83},[],{"trials":3999,"activeCount":83},[],{"trials":4001,"activeCount":83},[],{"intervention":884,"totalTrials":112,"cells":4003},{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4014,"PHASE4":4016,"NA":4018},{"trials":4005,"activeCount":83},[],{"trials":4007,"activeCount":83},[],{"trials":4009,"activeCount":83},[4010],{"nctId":875,"briefTitle":876,"status":91,"phases":4011,"primaryCompletion":385,"start":878,"enrollment":329,"conditions":4012,"interventions":4013},[73],[880],[882,883,426,884,885],{"trials":4015,"activeCount":83},[],{"trials":4017,"activeCount":83},[],{"trials":4019,"activeCount":83},[],{"intervention":885,"totalTrials":112,"cells":4021},{"EARLY_PHASE1":4022,"PHASE1":4024,"PHASE2":4026,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4023,"activeCount":83},[],{"trials":4025,"activeCount":83},[],{"trials":4027,"activeCount":83},[4028],{"nctId":875,"briefTitle":876,"status":91,"phases":4029,"primaryCompletion":385,"start":878,"enrollment":329,"conditions":4030,"interventions":4031},[73],[880],[882,883,426,884,885],{"trials":4033,"activeCount":83},[],{"trials":4035,"activeCount":83},[],{"trials":4037,"activeCount":83},[],{"intervention":3061,"totalTrials":112,"cells":4039},{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4044,"PHASE3":4050,"PHASE4":4052,"NA":4054},{"trials":4041,"activeCount":83},[],{"trials":4043,"activeCount":83},[],{"trials":4045,"activeCount":83},[4046],{"nctId":3052,"briefTitle":3053,"status":91,"phases":4047,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":4048,"interventions":4049},[73],[33],[917,3061,898],{"trials":4051,"activeCount":83},[],{"trials":4053,"activeCount":83},[],{"trials":4055,"activeCount":83},[],{"intervention":1104,"totalTrials":112,"cells":4057},{"EARLY_PHASE1":4058,"PHASE1":4060,"PHASE2":4062,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4059,"activeCount":83},[],{"trials":4061,"activeCount":83},[],{"trials":4063,"activeCount":83},[4064],{"nctId":1097,"briefTitle":1098,"status":91,"phases":4065,"primaryCompletion":1100,"completion":961,"start":1101,"conditions":4066,"interventions":4067},[73],[23],[283,1104,813],{"trials":4069,"activeCount":83},[],{"trials":4071,"activeCount":83},[],{"trials":4073,"activeCount":83},[],{"intervention":4075,"totalTrials":112,"cells":4076},"PEG-interferon alfa-2b",{"EARLY_PHASE1":4077,"PHASE1":4079,"PHASE2":4081,"PHASE3":4091,"PHASE4":4093,"NA":4095},{"trials":4078,"activeCount":83},[],{"trials":4080,"activeCount":83},[],{"trials":4082,"activeCount":83},[4083],{"nctId":4084,"briefTitle":4085,"status":91,"phases":4086,"primaryCompletion":240,"completion":4087,"start":4088,"enrollment":820,"conditions":4089,"interventions":4090},"NCT00049530","PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma",[73],"2014-06","2004-01-13",[30],[4075],{"trials":4092,"activeCount":83},[],{"trials":4094,"activeCount":83},[],{"trials":4096,"activeCount":83},[],{"intervention":4098,"totalTrials":112,"cells":4099},"Sorafenib",{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4104,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4101,"activeCount":83},[],{"trials":4103,"activeCount":83},[],{"trials":4105,"activeCount":83},[4106],{"nctId":4107,"briefTitle":4108,"status":91,"phases":4109,"primaryCompletion":1146,"completion":1146,"start":4110,"enrollment":4111,"conditions":4112,"interventions":4113},"NCT00064350","Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer",[73],"2004-06-28",342,[23],[4098],{"trials":4115,"activeCount":83},[],{"trials":4117,"activeCount":83},[],{"trials":4119,"activeCount":83},[],{"intervention":4121,"totalTrials":112,"cells":4122},"flecainide acetate",{"EARLY_PHASE1":4123,"PHASE1":4125,"PHASE2":4127,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4124,"activeCount":83},[],{"trials":4126,"activeCount":83},[],{"trials":4128,"activeCount":83},[4129],{"nctId":4130,"briefTitle":4131,"status":91,"phases":4132,"primaryCompletion":3955,"start":4133,"enrollment":16,"conditions":4134,"interventions":4135},"NCT00002996","Flecainide in Treating Patients With Chronic Neuropathic Pain",[73],"1998-05-04",[1264],[4121],{"trials":4137,"activeCount":83},[],{"trials":4139,"activeCount":83},[],{"trials":4141,"activeCount":83},[],{"intervention":1949,"totalTrials":112,"cells":4143},{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4148,"PHASE3":4154,"PHASE4":4156,"NA":4158},{"trials":4145,"activeCount":83},[],{"trials":4147,"activeCount":83},[],{"trials":4149,"activeCount":83},[4150],{"nctId":1941,"briefTitle":1942,"status":91,"phases":4151,"primaryCompletion":798,"completion":240,"start":1944,"enrollment":1945,"conditions":4152,"interventions":4153},[73],[1947,98],[332,217,1949],{"trials":4155,"activeCount":83},[],{"trials":4157,"activeCount":83},[],{"trials":4159,"activeCount":83},[],{"intervention":4161,"totalTrials":112,"cells":4162},"denileukin diftitox",{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4177,"PHASE4":4179,"NA":4181},{"trials":4164,"activeCount":83},[],{"trials":4166,"activeCount":83},[],{"trials":4168,"activeCount":83},[4169],{"nctId":4170,"briefTitle":4171,"status":91,"phases":4172,"primaryCompletion":868,"start":4173,"enrollment":4174,"conditions":4175,"interventions":4176},"NCT00003615","Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma",[73],"1999-05-20",77,[18],[4161],{"trials":4178,"activeCount":83},[],{"trials":4180,"activeCount":83},[],{"trials":4182,"activeCount":83},[],{"intervention":4184,"totalTrials":112,"cells":4185},"fowlpox virus vaccine vector",{"EARLY_PHASE1":4186,"PHASE1":4188,"PHASE2":4190,"PHASE3":4201,"PHASE4":4203,"NA":4205},{"trials":4187,"activeCount":83},[],{"trials":4189,"activeCount":83},[],{"trials":4191,"activeCount":83},[4192],{"nctId":4193,"briefTitle":4194,"status":91,"phases":4195,"primaryCompletion":3381,"start":4196,"enrollment":4197,"conditions":4198,"interventions":4199},"NCT00003871","PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer",[73],"1999-09-24",60,[27],[4184,4200],"recombinant vaccinia prostate-specific antigen vaccine",{"trials":4202,"activeCount":83},[],{"trials":4204,"activeCount":83},[],{"trials":4206,"activeCount":83},[],{"intervention":4200,"totalTrials":112,"cells":4208},{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4219,"PHASE4":4221,"NA":4223},{"trials":4210,"activeCount":83},[],{"trials":4212,"activeCount":83},[],{"trials":4214,"activeCount":83},[4215],{"nctId":4193,"briefTitle":4194,"status":91,"phases":4216,"primaryCompletion":3381,"start":4196,"enrollment":4197,"conditions":4217,"interventions":4218},[73],[27],[4184,4200],{"trials":4220,"activeCount":83},[],{"trials":4222,"activeCount":83},[],{"trials":4224,"activeCount":83},[],{"intervention":4226,"totalTrials":112,"cells":4227},"piritrexim",{"EARLY_PHASE1":4228,"PHASE1":4230,"PHASE2":4232,"PHASE3":4242,"PHASE4":4244,"NA":4246},{"trials":4229,"activeCount":83},[],{"trials":4231,"activeCount":83},[],{"trials":4233,"activeCount":83},[4234],{"nctId":4235,"briefTitle":4236,"status":91,"phases":4237,"primaryCompletion":4238,"completion":327,"start":4239,"enrollment":3323,"conditions":4240,"interventions":4241},"NCT00002914","Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract",[73],"2001-06","1997-07-15",[964,965,966],[4226],{"trials":4243,"activeCount":83},[],{"trials":4245,"activeCount":83},[],{"trials":4247,"activeCount":83},[],{"intervention":1829,"totalTrials":112,"cells":4249},{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4254,"PHASE3":4260,"PHASE4":4262,"NA":4264},{"trials":4251,"activeCount":83},[],{"trials":4253,"activeCount":83},[],{"trials":4255,"activeCount":83},[4256],{"nctId":1809,"briefTitle":1810,"status":1083,"phases":4257,"primaryCompletion":1812,"start":1812,"enrollment":83,"conditions":4258,"interventions":4259},[72,73],[1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827],[1829,1309,404,1013],{"trials":4261,"activeCount":83},[],{"trials":4263,"activeCount":83},[],{"trials":4265,"activeCount":83},[],{"intervention":4267,"totalTrials":112,"cells":4268},"AMG 706",{"EARLY_PHASE1":4269,"PHASE1":4271,"PHASE2":4273,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4270,"activeCount":83},[],{"trials":4272,"activeCount":83},[],{"trials":4274,"activeCount":83},[4275],{"nctId":4276,"briefTitle":4277,"status":91,"phases":4278,"primaryCompletion":4279,"completion":1777,"start":4280,"enrollment":213,"conditions":4281,"interventions":4284},"NCT00427349","AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors",[73],"2014-10","2008-11-07",[2084,4282,4283],"Islet Cell Tumor","Neoplastic Syndrome",[4267,4285],"octreotide",{"trials":4287,"activeCount":83},[],{"trials":4289,"activeCount":83},[],{"trials":4291,"activeCount":83},[],{"intervention":4285,"totalTrials":112,"cells":4293},{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4304,"PHASE4":4306,"NA":4308},{"trials":4295,"activeCount":83},[],{"trials":4297,"activeCount":83},[],{"trials":4299,"activeCount":83},[4300],{"nctId":4276,"briefTitle":4277,"status":91,"phases":4301,"primaryCompletion":4279,"completion":1777,"start":4280,"enrollment":213,"conditions":4302,"interventions":4303},[73],[2084,4282,4283],[4267,4285],{"trials":4305,"activeCount":83},[],{"trials":4307,"activeCount":83},[],{"trials":4309,"activeCount":83},[],{"intervention":4311,"totalTrials":112,"cells":4312},"valrubicin",{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4317,"PHASE3":4328,"PHASE4":4330,"NA":4332},{"trials":4314,"activeCount":83},[],{"trials":4316,"activeCount":83},[],{"trials":4318,"activeCount":83},[4319],{"nctId":4320,"briefTitle":4321,"status":91,"phases":4322,"primaryCompletion":4323,"completion":1363,"start":4324,"enrollment":4325,"conditions":4326,"interventions":4327},"NCT00003129","Chemotherapy in Treating Patients With Early-Stage Bladder Cancer",[73],"2002-11","1998-09-01",75,[964],[4311],{"trials":4329,"activeCount":83},[],{"trials":4331,"activeCount":83},[],{"trials":4333,"activeCount":83},[],{"intervention":1724,"totalTrials":112,"cells":4335},{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4337,"activeCount":83},[],{"trials":4339,"activeCount":83},[],{"trials":4341,"activeCount":83},[4342],{"nctId":1715,"briefTitle":1716,"status":91,"phases":4343,"primaryCompletion":1718,"completion":1719,"start":1720,"enrollment":1721,"conditions":4344,"interventions":4345},[73],[30],[1653,1724,1725,268,1726],{"trials":4347,"activeCount":83},[],{"trials":4349,"activeCount":83},[],{"trials":4351,"activeCount":83},[],{"intervention":1725,"totalTrials":112,"cells":4353},{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4364,"PHASE4":4366,"NA":4368},{"trials":4355,"activeCount":83},[],{"trials":4357,"activeCount":83},[],{"trials":4359,"activeCount":83},[4360],{"nctId":1715,"briefTitle":1716,"status":91,"phases":4361,"primaryCompletion":1718,"completion":1719,"start":1720,"enrollment":1721,"conditions":4362,"interventions":4363},[73],[30],[1653,1724,1725,268,1726],{"trials":4365,"activeCount":83},[],{"trials":4367,"activeCount":83},[],{"trials":4369,"activeCount":83},[],{"intervention":1726,"totalTrials":112,"cells":4371},{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4382,"PHASE4":4384,"NA":4386},{"trials":4373,"activeCount":83},[],{"trials":4375,"activeCount":83},[],{"trials":4377,"activeCount":83},[4378],{"nctId":1715,"briefTitle":1716,"status":91,"phases":4379,"primaryCompletion":1718,"completion":1719,"start":1720,"enrollment":1721,"conditions":4380,"interventions":4381},[73],[30],[1653,1724,1725,268,1726],{"trials":4383,"activeCount":83},[],{"trials":4385,"activeCount":83},[],{"trials":4387,"activeCount":83},[],{"intervention":4389,"totalTrials":112,"cells":4390},"gefitinib",{"EARLY_PHASE1":4391,"PHASE1":4393,"PHASE2":4395,"PHASE3":4404,"PHASE4":4406,"NA":4408},{"trials":4392,"activeCount":83},[],{"trials":4394,"activeCount":83},[],{"trials":4396,"activeCount":83},[4397],{"nctId":4398,"briefTitle":4399,"status":91,"phases":4400,"completion":385,"start":4401,"conditions":4402,"interventions":4403},"NCT00025350","Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer",[73],"2001-10",[33],[4389],{"trials":4405,"activeCount":83},[],{"trials":4407,"activeCount":83},[],{"trials":4409,"activeCount":83},[],{"intervention":4411,"totalTrials":112,"cells":4412},"cetuximab C225",{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4417,"PHASE3":4429,"PHASE4":4431,"NA":4433},{"trials":4414,"activeCount":83},[],{"trials":4416,"activeCount":83},[],{"trials":4418,"activeCount":83},[4419],{"nctId":4420,"briefTitle":4421,"status":91,"phases":4422,"primaryCompletion":4423,"completion":4424,"start":4425,"enrollment":4426,"conditions":4427,"interventions":4428},"NCT00096174","Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck",[73],"2009-07","2016-07","2005-04-08",69,[25],[4411,332],{"trials":4430,"activeCount":83},[],{"trials":4432,"activeCount":83},[],{"trials":4434,"activeCount":83},[],{"intervention":4436,"totalTrials":112,"cells":4437},"carboxyamidotriazole",{"EARLY_PHASE1":4438,"PHASE1":4440,"PHASE2":4442,"PHASE3":4451,"PHASE4":4453,"NA":4455},{"trials":4439,"activeCount":83},[],{"trials":4441,"activeCount":83},[],{"trials":4443,"activeCount":83},[4444],{"nctId":4445,"briefTitle":4446,"status":91,"phases":4447,"completion":4448,"start":2301,"conditions":4449,"interventions":4450},"NCT00005045","Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer",[73],"2004-06",[872],[4436],{"trials":4452,"activeCount":83},[],{"trials":4454,"activeCount":83},[],{"trials":4456,"activeCount":83},[],{"intervention":944,"totalTrials":112,"cells":4458},{"EARLY_PHASE1":4459,"PHASE1":4461,"PHASE2":4463,"PHASE3":4469,"PHASE4":4471,"NA":4473},{"trials":4460,"activeCount":83},[],{"trials":4462,"activeCount":83},[],{"trials":4464,"activeCount":83},[4465],{"nctId":938,"briefTitle":939,"status":91,"phases":4466,"completion":846,"start":941,"conditions":4467,"interventions":4468},[73],[23],[944,283,426],{"trials":4470,"activeCount":83},[],{"trials":4472,"activeCount":83},[],{"trials":4474,"activeCount":83},[],{"intervention":1879,"totalTrials":112,"cells":4476},{"EARLY_PHASE1":4477,"PHASE1":4479,"PHASE2":4481,"PHASE3":4487,"PHASE4":4489,"NA":4491},{"trials":4478,"activeCount":83},[],{"trials":4480,"activeCount":83},[],{"trials":4482,"activeCount":83},[4483],{"nctId":1873,"briefTitle":1874,"status":91,"phases":4484,"primaryCompletion":263,"start":1876,"conditions":4485,"interventions":4486},[73],[33],[404,1879],{"trials":4488,"activeCount":83},[],{"trials":4490,"activeCount":83},[],{"trials":4492,"activeCount":83},[],{"intervention":1961,"totalTrials":112,"cells":4494},{"EARLY_PHASE1":4495,"PHASE1":4497,"PHASE2":4499,"PHASE3":4505,"PHASE4":4507,"NA":4509},{"trials":4496,"activeCount":83},[],{"trials":4498,"activeCount":83},[],{"trials":4500,"activeCount":83},[4501],{"nctId":1951,"briefTitle":1952,"status":91,"phases":4502,"primaryCompletion":497,"completion":798,"start":1954,"enrollment":1955,"conditions":4503,"interventions":4504},[73],[1957,1958],[244,1960,1549,1961],{"trials":4506,"activeCount":83},[],{"trials":4508,"activeCount":83},[],{"trials":4510,"activeCount":83},[],{"intervention":470,"totalTrials":112,"cells":4512},{"EARLY_PHASE1":4513,"PHASE1":4515,"PHASE2":4517,"PHASE3":4523,"PHASE4":4525,"NA":4527},{"trials":4514,"activeCount":83},[],{"trials":4516,"activeCount":83},[],{"trials":4518,"activeCount":83},[4519],{"nctId":462,"briefTitle":463,"status":237,"phases":4520,"primaryCompletion":465,"completion":465,"start":466,"enrollment":96,"conditions":4521,"interventions":4522},[73],[18],[469,44,178,470,310,471,246],{"trials":4524,"activeCount":83},[],{"trials":4526,"activeCount":83},[],{"trials":4528,"activeCount":83},[],{"intervention":471,"totalTrials":112,"cells":4530},{"EARLY_PHASE1":4531,"PHASE1":4533,"PHASE2":4535,"PHASE3":4541,"PHASE4":4543,"NA":4545},{"trials":4532,"activeCount":83},[],{"trials":4534,"activeCount":83},[],{"trials":4536,"activeCount":83},[4537],{"nctId":462,"briefTitle":463,"status":237,"phases":4538,"primaryCompletion":465,"completion":465,"start":466,"enrollment":96,"conditions":4539,"interventions":4540},[73],[18],[469,44,178,470,310,471,246],{"trials":4542,"activeCount":83},[],{"trials":4544,"activeCount":83},[],{"trials":4546,"activeCount":83},[],{"intervention":4548,"totalTrials":79,"cells":4549},"Ad5CMV-p53 gene",{"EARLY_PHASE1":4550,"PHASE1":4552,"PHASE2":4568,"PHASE3":4570,"PHASE4":4572,"NA":4574},{"trials":4551,"activeCount":83},[],{"trials":4553,"activeCount":83},[4554,4561],{"nctId":4555,"briefTitle":4556,"status":91,"phases":4557,"start":4558,"conditions":4559,"interventions":4560},"NCT00004225","Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer",[72],"2000-01",[23],[4548],{"nctId":4562,"briefTitle":4563,"status":91,"phases":4564,"completion":961,"start":4565,"conditions":4566,"interventions":4567},"NCT00003649","Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed",[72],"1998-11-17",[23],[4548],{"trials":4569,"activeCount":83},[],{"trials":4571,"activeCount":83},[],{"trials":4573,"activeCount":83},[],{"trials":4575,"activeCount":83},[],{"intervention":1151,"totalTrials":112,"cells":4577},{"EARLY_PHASE1":4578,"PHASE1":4580,"PHASE2":4586,"PHASE3":4588,"PHASE4":4590,"NA":4592},{"trials":4579,"activeCount":83},[],{"trials":4581,"activeCount":83},[4582],{"nctId":1142,"briefTitle":1143,"status":237,"phases":4583,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":433,"conditions":4584,"interventions":4585},[72],[1149,295],[229,1151,299],{"trials":4587,"activeCount":83},[],{"trials":4589,"activeCount":83},[],{"trials":4591,"activeCount":83},[],{"trials":4593,"activeCount":83},[],{"intervention":332,"totalTrials":11,"cells":4595},{"EARLY_PHASE1":4596,"PHASE1":4598,"PHASE2":4600,"PHASE3":4642,"PHASE4":4667,"NA":4669},{"trials":4597,"activeCount":83},[],{"trials":4599,"activeCount":83},[],{"trials":4601,"activeCount":83},[4602,4606,4610,4614,4618,4622,4626,4630,4634,4638],{"nctId":1530,"briefTitle":1531,"status":91,"phases":4603,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":4604,"interventions":4605},[73],[23],[216,332,285],{"nctId":1540,"briefTitle":1541,"status":91,"phases":4607,"primaryCompletion":1543,"completion":240,"start":1544,"enrollment":1545,"conditions":4608,"interventions":4609},[73],[1547],[1549,919,368,1550,1551],{"nctId":806,"briefTitle":807,"status":91,"phases":4611,"primaryCompletion":809,"start":810,"conditions":4612,"interventions":4613},[73],[23],[283,332,813,426],{"nctId":324,"briefTitle":325,"status":91,"phases":4615,"primaryCompletion":327,"start":328,"enrollment":329,"conditions":4616,"interventions":4617},[73],[109],[229,332,198,285,322],{"nctId":1941,"briefTitle":1942,"status":91,"phases":4619,"primaryCompletion":798,"completion":240,"start":1944,"enrollment":1945,"conditions":4620,"interventions":4621},[73],[1947,98],[332,217,1949],{"nctId":887,"briefTitle":888,"status":91,"phases":4623,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":4624,"interventions":4625},[73],[895,896],[332,898,426],{"nctId":908,"briefTitle":909,"status":91,"phases":4627,"primaryCompletion":911,"completion":911,"start":912,"enrollment":913,"conditions":4628,"interventions":4629},[73],[25,915],[917,918,919],{"nctId":4420,"briefTitle":4421,"status":91,"phases":4631,"primaryCompletion":4423,"completion":4424,"start":4425,"enrollment":4426,"conditions":4632,"interventions":4633},[73],[25],[4411,332],{"nctId":969,"briefTitle":970,"status":91,"phases":4635,"primaryCompletion":972,"start":973,"enrollment":974,"conditions":4636,"interventions":4637},[73],[895,896],[332,426],{"nctId":1186,"briefTitle":1187,"status":91,"phases":4639,"primaryCompletion":263,"completion":925,"start":1189,"conditions":4640,"interventions":4641},[73],[1191],[541,229,332,1013,813],{"trials":4643,"activeCount":83},[4644,4648,4652,4656,4660],{"nctId":987,"briefTitle":988,"status":91,"phases":4645,"primaryCompletion":990,"start":991,"enrollment":992,"conditions":4646,"interventions":4647},[74],[964,965,966],[283,332,284,320,426,995],{"nctId":1215,"briefTitle":1216,"status":91,"phases":4649,"primaryCompletion":1218,"start":1219,"enrollment":1220,"conditions":4650,"interventions":4651},[74],[30],[1223,229,482,332,1224,995],{"nctId":1006,"briefTitle":1007,"status":91,"phases":4653,"completion":1009,"start":1010,"conditions":4654,"interventions":4655},[74],[25],[332,1013,426],{"nctId":1015,"briefTitle":1016,"status":91,"phases":4657,"primaryCompletion":1018,"completion":961,"start":1019,"enrollment":1020,"conditions":4658,"interventions":4659},[74],[964,966],[283,332,284,320,426,1023],{"nctId":4661,"briefTitle":4662,"status":91,"phases":4663,"primaryCompletion":1158,"start":4664,"conditions":4665,"interventions":4666},"NCT00003809","Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer",[74],"1999-08-06",[25],[917,332],{"trials":4668,"activeCount":83},[],{"trials":4670,"activeCount":83},[4671],{"nctId":4672,"briefTitle":4673,"status":91,"phases":4674,"primaryCompletion":4675,"completion":4675,"start":4676,"enrollment":4677,"conditions":4678,"interventions":4679},"NCT01466244","Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397",[],"2012-01-11","2011-11-11",42,[25],[917,332,775,4680],"microarray analysis",{"intervention":775,"totalTrials":705,"cells":4682},{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4689,"PHASE4":4691,"NA":4693},{"trials":4684,"activeCount":83},[],{"trials":4686,"activeCount":83},[],{"trials":4688,"activeCount":83},[],{"trials":4690,"activeCount":83},[],{"trials":4692,"activeCount":83},[],{"trials":4694,"activeCount":83},[4695,4703,4713,4717,4721,4731,4740,4752,4764,4772],{"nctId":4696,"briefTitle":4697,"status":91,"phases":4698,"primaryCompletion":1000,"start":4699,"enrollment":2100,"conditions":4700,"interventions":4701},"NCT00899418","Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100",[],"2006-05",[20],[775,776,4702],"polymorphism analysis",{"nctId":4704,"briefTitle":4705,"status":91,"phases":4706,"primaryCompletion":4707,"completion":4707,"start":4708,"enrollment":3323,"conditions":4709,"interventions":4710},"NCT00897559","Study of Bone Marrow Samples From Patients With Acute Leukemia",[],"2009-11-11","2008-07-03",[15],[775,4711,4702,4712],"mutation analysis","protein analysis",{"nctId":4672,"briefTitle":4673,"status":91,"phases":4714,"primaryCompletion":4675,"completion":4675,"start":4676,"enrollment":4677,"conditions":4715,"interventions":4716},[],[25],[917,332,775,4680],{"nctId":766,"briefTitle":767,"status":91,"phases":4718,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":4719,"interventions":4720},[],[18],[39,774,775,776],{"nctId":4722,"briefTitle":4723,"status":91,"phases":4724,"primaryCompletion":4725,"completion":4725,"start":4726,"enrollment":4727,"conditions":4728,"interventions":4729},"NCT01487733","Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301",[],"2012-01-22","2011-12-22",155,[25],[775,4730],"in situ hybridization",{"nctId":4732,"briefTitle":4733,"status":91,"phases":4734,"primaryCompletion":4735,"completion":4735,"start":4736,"enrollment":4737,"conditions":4738,"interventions":4739},"NCT01145469","Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy",[],"2010-08-01","2010-06-01",225,[15],[774,775,4702],{"nctId":4741,"briefTitle":4742,"status":91,"phases":4743,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":4746,"conditions":4747,"interventions":4748},"NCT01421875","Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia",[],"2011-10-17","2011-08-17",257,[15],[4749,4750,775,4680,4751],"DNA methylation analysis","RNA analysis","nucleic acid sequencing",{"nctId":4753,"briefTitle":4754,"status":4755,"phases":4756,"primaryCompletion":4757,"start":4758,"enrollment":4759,"conditions":4760,"interventions":4761},"NCT01653613","Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia","UNKNOWN",[],"2013-02","2010-08",400,[15],[774,4762,775,4680,4711,4702,4763],"fluorescence in situ hybridization","reverse transcriptase-polymerase chain reaction",{"nctId":4765,"briefTitle":4766,"status":91,"phases":4767,"primaryCompletion":4768,"completion":4768,"start":4769,"enrollment":329,"conditions":4770,"interventions":4771},"NCT00899080","Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide",[],"2008-08-04","2008-07-04",[295],[775,4763],{"nctId":4773,"briefTitle":4774,"status":91,"phases":4775,"primaryCompletion":4776,"completion":4776,"start":4777,"enrollment":4778,"conditions":4779,"interventions":4780},"NCT01150643","Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab",[],"2011-01-06","2010-12-06",559,[18],[775,4680,776,4702],{"intervention":917,"totalTrials":433,"cells":4782},{"EARLY_PHASE1":4783,"PHASE1":4785,"PHASE2":4787,"PHASE3":4818,"PHASE4":4824,"NA":4826},{"trials":4784,"activeCount":83},[],{"trials":4786,"activeCount":83},[],{"trials":4788,"activeCount":83},[4789,4793,4797,4801,4810,4814],{"nctId":1327,"briefTitle":1328,"status":237,"phases":4790,"primaryCompletion":1330,"completion":1331,"start":1332,"enrollment":870,"conditions":4791,"interventions":4792},[73],[895],[1335,1336,954,1337],{"nctId":3052,"briefTitle":3053,"status":91,"phases":4794,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":4795,"interventions":4796},[73],[33],[917,3061,898],{"nctId":1347,"briefTitle":1348,"status":91,"phases":4798,"primaryCompletion":497,"completion":1350,"start":1351,"enrollment":1352,"conditions":4799,"interventions":4800},[73],[1191],[917,416,898],{"nctId":4802,"briefTitle":4803,"status":91,"phases":4804,"primaryCompletion":4805,"completion":240,"start":4806,"enrollment":4807,"conditions":4808,"interventions":4809},"NCT00103207","Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer",[73],"2010-04","2005-10-13",72,[23],[917],{"nctId":908,"briefTitle":909,"status":91,"phases":4811,"primaryCompletion":911,"completion":911,"start":912,"enrollment":913,"conditions":4812,"interventions":4813},[73],[25,915],[917,918,919],{"nctId":946,"briefTitle":947,"status":91,"phases":4815,"primaryCompletion":949,"completion":950,"start":951,"enrollment":174,"conditions":4816,"interventions":4817},[73],[25],[954,955,918],{"trials":4819,"activeCount":83},[4820],{"nctId":4661,"briefTitle":4662,"status":91,"phases":4821,"primaryCompletion":1158,"start":4664,"conditions":4822,"interventions":4823},[74],[25],[917,332],{"trials":4825,"activeCount":83},[],{"trials":4827,"activeCount":83},[4828],{"nctId":4672,"briefTitle":4673,"status":91,"phases":4829,"primaryCompletion":4675,"completion":4675,"start":4676,"enrollment":4677,"conditions":4830,"interventions":4831},[],[25],[917,332,775,4680],{"intervention":4680,"totalTrials":1433,"cells":4833},{"EARLY_PHASE1":4834,"PHASE1":4836,"PHASE2":4838,"PHASE3":4840,"PHASE4":4842,"NA":4844},{"trials":4835,"activeCount":83},[],{"trials":4837,"activeCount":83},[],{"trials":4839,"activeCount":83},[],{"trials":4841,"activeCount":83},[],{"trials":4843,"activeCount":83},[],{"trials":4845,"activeCount":83},[4846,4856,4860,4873,4877,4881],{"nctId":4847,"briefTitle":4848,"status":91,"phases":4849,"primaryCompletion":4850,"completion":4850,"start":4851,"enrollment":4852,"conditions":4853,"interventions":4854},"NCT01505699","Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia",[],"2012-02-06","2012-01-06",186,[15],[4750,4855,4680],"cytogenetic analysis",{"nctId":4672,"briefTitle":4673,"status":91,"phases":4857,"primaryCompletion":4675,"completion":4675,"start":4676,"enrollment":4677,"conditions":4858,"interventions":4859},[],[25],[917,332,775,4680],{"nctId":4861,"briefTitle":4862,"status":91,"phases":4863,"primaryCompletion":4864,"completion":4864,"start":4865,"enrollment":4866,"conditions":4867,"interventions":4871},"NCT00897299","Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy",[],"2005-10-08","2005-10-07",900,[20,4868,4869,4870],"Estrogen Receptor","Her-2","Pgr",[4680,4872],"protein expression analysis",{"nctId":4741,"briefTitle":4742,"status":91,"phases":4874,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":4746,"conditions":4875,"interventions":4876},[],[15],[4749,4750,775,4680,4751],{"nctId":4753,"briefTitle":4754,"status":4755,"phases":4878,"primaryCompletion":4757,"start":4758,"enrollment":4759,"conditions":4879,"interventions":4880},[],[15],[774,4762,775,4680,4711,4702,4763],{"nctId":4773,"briefTitle":4774,"status":91,"phases":4882,"primaryCompletion":4776,"completion":4776,"start":4777,"enrollment":4778,"conditions":4883,"interventions":4884},[],[18],[775,4680,776,4702],{"intervention":776,"totalTrials":1433,"cells":4886},{"EARLY_PHASE1":4887,"PHASE1":4889,"PHASE2":4891,"PHASE3":4893,"PHASE4":4895,"NA":4897},{"trials":4888,"activeCount":83},[],{"trials":4890,"activeCount":83},[],{"trials":4892,"activeCount":83},[],{"trials":4894,"activeCount":83},[],{"trials":4896,"activeCount":83},[],{"trials":4898,"activeCount":83},[4899,4908,4917,4921,4930,4934],{"nctId":4900,"briefTitle":4901,"status":91,"phases":4902,"primaryCompletion":4903,"completion":4903,"start":4904,"enrollment":4905,"conditions":4906,"interventions":4907},"NCT01619618","Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial",[],"2012-07-01","2012-06-01",183,[25],[4711,776,4702],{"nctId":4909,"briefTitle":4910,"status":91,"phases":4911,"primaryCompletion":4912,"completion":4912,"start":4913,"enrollment":4914,"conditions":4915,"interventions":4916},"NCT01489423","Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim",[],"2013-05-26","2013-04-26",270,[30],[4750,4730,776],{"nctId":4696,"briefTitle":4697,"status":91,"phases":4918,"primaryCompletion":1000,"start":4699,"enrollment":2100,"conditions":4919,"interventions":4920},[],[20],[775,776,4702],{"nctId":4922,"briefTitle":4923,"status":91,"phases":4924,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":820,"conditions":4927,"interventions":4928},"NCT01390597","Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms",[],"2011-08-28","2011-06-28",[18],[774,4855,4929,4711,776],"gene mapping",{"nctId":766,"briefTitle":767,"status":91,"phases":4931,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":4932,"interventions":4933},[],[18],[39,774,775,776],{"nctId":4773,"briefTitle":4774,"status":91,"phases":4935,"primaryCompletion":4776,"completion":4776,"start":4777,"enrollment":4778,"conditions":4936,"interventions":4937},[],[18],[775,4680,776,4702],{"intervention":4702,"totalTrials":1433,"cells":4939},{"EARLY_PHASE1":4940,"PHASE1":4942,"PHASE2":4944,"PHASE3":4946,"PHASE4":4948,"NA":4950},{"trials":4941,"activeCount":83},[],{"trials":4943,"activeCount":83},[],{"trials":4945,"activeCount":83},[],{"trials":4947,"activeCount":83},[],{"trials":4949,"activeCount":83},[],{"trials":4951,"activeCount":83},[4952,4956,4960,4964,4968,4972],{"nctId":4900,"briefTitle":4901,"status":91,"phases":4953,"primaryCompletion":4903,"completion":4903,"start":4904,"enrollment":4905,"conditions":4954,"interventions":4955},[],[25],[4711,776,4702],{"nctId":4696,"briefTitle":4697,"status":91,"phases":4957,"primaryCompletion":1000,"start":4699,"enrollment":2100,"conditions":4958,"interventions":4959},[],[20],[775,776,4702],{"nctId":4704,"briefTitle":4705,"status":91,"phases":4961,"primaryCompletion":4707,"completion":4707,"start":4708,"enrollment":3323,"conditions":4962,"interventions":4963},[],[15],[775,4711,4702,4712],{"nctId":4732,"briefTitle":4733,"status":91,"phases":4965,"primaryCompletion":4735,"completion":4735,"start":4736,"enrollment":4737,"conditions":4966,"interventions":4967},[],[15],[774,775,4702],{"nctId":4753,"briefTitle":4754,"status":4755,"phases":4969,"primaryCompletion":4757,"start":4758,"enrollment":4759,"conditions":4970,"interventions":4971},[],[15],[774,4762,775,4680,4711,4702,4763],{"nctId":4773,"briefTitle":4774,"status":91,"phases":4973,"primaryCompletion":4776,"completion":4776,"start":4777,"enrollment":4778,"conditions":4974,"interventions":4975},[],[18],[775,4680,776,4702],{"intervention":4711,"totalTrials":509,"cells":4977},{"EARLY_PHASE1":4978,"PHASE1":4980,"PHASE2":4982,"PHASE3":4984,"PHASE4":4986,"NA":4988},{"trials":4979,"activeCount":83},[],{"trials":4981,"activeCount":83},[],{"trials":4983,"activeCount":83},[],{"trials":4985,"activeCount":83},[],{"trials":4987,"activeCount":83},[],{"trials":4989,"activeCount":83},[4990,4994,4998,5002,5011],{"nctId":4900,"briefTitle":4901,"status":91,"phases":4991,"primaryCompletion":4903,"completion":4903,"start":4904,"enrollment":4905,"conditions":4992,"interventions":4993},[],[25],[4711,776,4702],{"nctId":4922,"briefTitle":4923,"status":91,"phases":4995,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":820,"conditions":4996,"interventions":4997},[],[18],[774,4855,4929,4711,776],{"nctId":4704,"briefTitle":4705,"status":91,"phases":4999,"primaryCompletion":4707,"completion":4707,"start":4708,"enrollment":3323,"conditions":5000,"interventions":5001},[],[15],[775,4711,4702,4712],{"nctId":5003,"briefTitle":5004,"status":91,"phases":5005,"primaryCompletion":5006,"completion":5006,"start":5007,"enrollment":5008,"conditions":5009,"interventions":5010},"NCT01385150","Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia",[],"2012-02-03","2012-01-03",220,[15],[4711,4712],{"nctId":4753,"briefTitle":4754,"status":4755,"phases":5012,"primaryCompletion":4757,"start":4758,"enrollment":4759,"conditions":5013,"interventions":5014},[],[15],[774,4762,775,4680,4711,4702,4763],{"intervention":774,"totalTrials":2007,"cells":5016},{"EARLY_PHASE1":5017,"PHASE1":5019,"PHASE2":5021,"PHASE3":5023,"PHASE4":5025,"NA":5027},{"trials":5018,"activeCount":83},[],{"trials":5020,"activeCount":83},[],{"trials":5022,"activeCount":83},[],{"trials":5024,"activeCount":83},[],{"trials":5026,"activeCount":83},[],{"trials":5028,"activeCount":83},[5029,5033,5037,5041],{"nctId":4922,"briefTitle":4923,"status":91,"phases":5030,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":820,"conditions":5031,"interventions":5032},[],[18],[774,4855,4929,4711,776],{"nctId":766,"briefTitle":767,"status":91,"phases":5034,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":5035,"interventions":5036},[],[18],[39,774,775,776],{"nctId":4732,"briefTitle":4733,"status":91,"phases":5038,"primaryCompletion":4735,"completion":4735,"start":4736,"enrollment":4737,"conditions":5039,"interventions":5040},[],[15],[774,775,4702],{"nctId":4753,"briefTitle":4754,"status":4755,"phases":5042,"primaryCompletion":4757,"start":4758,"enrollment":4759,"conditions":5043,"interventions":5044},[],[15],[774,4762,775,4680,4711,4702,4763],{"intervention":4750,"totalTrials":2038,"cells":5046},{"EARLY_PHASE1":5047,"PHASE1":5049,"PHASE2":5051,"PHASE3":5053,"PHASE4":5055,"NA":5057},{"trials":5048,"activeCount":83},[],{"trials":5050,"activeCount":83},[],{"trials":5052,"activeCount":83},[],{"trials":5054,"activeCount":83},[],{"trials":5056,"activeCount":83},[],{"trials":5058,"activeCount":83},[5059,5063,5067],{"nctId":4847,"briefTitle":4848,"status":91,"phases":5060,"primaryCompletion":4850,"completion":4850,"start":4851,"enrollment":4852,"conditions":5061,"interventions":5062},[],[15],[4750,4855,4680],{"nctId":4909,"briefTitle":4910,"status":91,"phases":5064,"primaryCompletion":4912,"completion":4912,"start":4913,"enrollment":4914,"conditions":5065,"interventions":5066},[],[30],[4750,4730,776],{"nctId":4741,"briefTitle":4742,"status":91,"phases":5068,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":4746,"conditions":5069,"interventions":5070},[],[15],[4749,4750,775,4680,4751],{"intervention":4855,"totalTrials":79,"cells":5072},{"EARLY_PHASE1":5073,"PHASE1":5075,"PHASE2":5077,"PHASE3":5079,"PHASE4":5081,"NA":5083},{"trials":5074,"activeCount":83},[],{"trials":5076,"activeCount":83},[],{"trials":5078,"activeCount":83},[],{"trials":5080,"activeCount":83},[],{"trials":5082,"activeCount":83},[],{"trials":5084,"activeCount":83},[5085,5089],{"nctId":4847,"briefTitle":4848,"status":91,"phases":5086,"primaryCompletion":4850,"completion":4850,"start":4851,"enrollment":4852,"conditions":5087,"interventions":5088},[],[15],[4750,4855,4680],{"nctId":4922,"briefTitle":4923,"status":91,"phases":5090,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":820,"conditions":5091,"interventions":5092},[],[18],[774,4855,4929,4711,776],{"intervention":4730,"totalTrials":79,"cells":5094},{"EARLY_PHASE1":5095,"PHASE1":5097,"PHASE2":5099,"PHASE3":5101,"PHASE4":5103,"NA":5105},{"trials":5096,"activeCount":83},[],{"trials":5098,"activeCount":83},[],{"trials":5100,"activeCount":83},[],{"trials":5102,"activeCount":83},[],{"trials":5104,"activeCount":83},[],{"trials":5106,"activeCount":83},[5107,5111],{"nctId":4909,"briefTitle":4910,"status":91,"phases":5108,"primaryCompletion":4912,"completion":4912,"start":4913,"enrollment":4914,"conditions":5109,"interventions":5110},[],[30],[4750,4730,776],{"nctId":4722,"briefTitle":4723,"status":91,"phases":5112,"primaryCompletion":4725,"completion":4725,"start":4726,"enrollment":4727,"conditions":5113,"interventions":5114},[],[25],[775,4730],{"intervention":4929,"totalTrials":79,"cells":5116},{"EARLY_PHASE1":5117,"PHASE1":5119,"PHASE2":5121,"PHASE3":5123,"PHASE4":5125,"NA":5127},{"trials":5118,"activeCount":83},[],{"trials":5120,"activeCount":83},[],{"trials":5122,"activeCount":83},[],{"trials":5124,"activeCount":83},[],{"trials":5126,"activeCount":83},[],{"trials":5128,"activeCount":83},[5129,5133],{"nctId":4922,"briefTitle":4923,"status":91,"phases":5130,"primaryCompletion":4925,"completion":4925,"start":4926,"enrollment":820,"conditions":5131,"interventions":5132},[],[18],[774,4855,4929,4711,776],{"nctId":5134,"briefTitle":5135,"status":91,"phases":5136,"primaryCompletion":5137,"start":5138,"enrollment":5139,"conditions":5140,"interventions":5141},"NCT00003329","Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer",[],"2007-12","1998-04-07",4000,[20,33,23,27],[4929],{"intervention":4712,"totalTrials":79,"cells":5143},{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5148,"PHASE3":5150,"PHASE4":5152,"NA":5154},{"trials":5145,"activeCount":83},[],{"trials":5147,"activeCount":83},[],{"trials":5149,"activeCount":83},[],{"trials":5151,"activeCount":83},[],{"trials":5153,"activeCount":83},[],{"trials":5155,"activeCount":83},[5156,5160],{"nctId":4704,"briefTitle":4705,"status":91,"phases":5157,"primaryCompletion":4707,"completion":4707,"start":4708,"enrollment":3323,"conditions":5158,"interventions":5159},[],[15],[775,4711,4702,4712],{"nctId":5003,"briefTitle":5004,"status":91,"phases":5161,"primaryCompletion":5006,"completion":5006,"start":5007,"enrollment":5008,"conditions":5162,"interventions":5163},[],[15],[4711,4712],{"intervention":4763,"totalTrials":79,"cells":5165},{"EARLY_PHASE1":5166,"PHASE1":5168,"PHASE2":5170,"PHASE3":5172,"PHASE4":5174,"NA":5176},{"trials":5167,"activeCount":83},[],{"trials":5169,"activeCount":83},[],{"trials":5171,"activeCount":83},[],{"trials":5173,"activeCount":83},[],{"trials":5175,"activeCount":83},[],{"trials":5177,"activeCount":83},[5178,5182],{"nctId":4753,"briefTitle":4754,"status":4755,"phases":5179,"primaryCompletion":4757,"start":4758,"enrollment":4759,"conditions":5180,"interventions":5181},[],[15],[774,4762,775,4680,4711,4702,4763],{"nctId":4765,"briefTitle":4766,"status":91,"phases":5183,"primaryCompletion":4768,"completion":4768,"start":4769,"enrollment":329,"conditions":5184,"interventions":5185},[],[295],[775,4763],{"intervention":5187,"totalTrials":112,"cells":5188},"paclitaxel albumin-stabilized nanoparticle formulation",{"EARLY_PHASE1":5189,"PHASE1":5191,"PHASE2":5193,"PHASE3":5195,"PHASE4":5197,"NA":5199},{"trials":5190,"activeCount":83},[],{"trials":5192,"activeCount":83},[],{"trials":5194,"activeCount":83},[],{"trials":5196,"activeCount":83},[],{"trials":5198,"activeCount":83},[],{"trials":5200,"activeCount":83},[5201],{"nctId":5202,"briefTitle":5203,"status":1083,"phases":5204,"start":348,"enrollment":83,"conditions":5205,"interventions":5207},"NCT00499291","Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors",[76],[5206],"Cancer",[5187],{"intervention":5209,"totalTrials":112,"cells":5210},"celecoxib",{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5215,"PHASE3":5217,"PHASE4":5219,"NA":5221},{"trials":5212,"activeCount":83},[],{"trials":5214,"activeCount":83},[],{"trials":5216,"activeCount":83},[],{"trials":5218,"activeCount":83},[],{"trials":5220,"activeCount":83},[],{"trials":5222,"activeCount":83},[5223],{"nctId":5224,"briefTitle":5225,"status":1083,"phases":5226,"enrollment":83,"conditions":5227,"interventions":5229},"NCT00093678","Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer",[76],[5228,18,30,839,1264,880,2581],"Cachexia",[5209],{"intervention":5231,"totalTrials":112,"cells":5232},"nicotine",{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5237,"PHASE3":5239,"PHASE4":5241,"NA":5243},{"trials":5234,"activeCount":83},[],{"trials":5236,"activeCount":83},[],{"trials":5238,"activeCount":83},[],{"trials":5240,"activeCount":83},[],{"trials":5242,"activeCount":83},[],{"trials":5244,"activeCount":83},[5245],{"nctId":5246,"briefTitle":5247,"status":91,"phases":5248,"primaryCompletion":5249,"start":5250,"enrollment":5251,"conditions":5252,"interventions":5254},"NCT00002520","Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer",[76],"2002-02","1990-12-07",434,[964,20,33,25,23,18,27,840,5253,2581],"Tobacco Use Disorder",[5231],{"intervention":4872,"totalTrials":112,"cells":5256},{"EARLY_PHASE1":5257,"PHASE1":5259,"PHASE2":5261,"PHASE3":5263,"PHASE4":5265,"NA":5267},{"trials":5258,"activeCount":83},[],{"trials":5260,"activeCount":83},[],{"trials":5262,"activeCount":83},[],{"trials":5264,"activeCount":83},[],{"trials":5266,"activeCount":83},[],{"trials":5268,"activeCount":83},[5269],{"nctId":4861,"briefTitle":4862,"status":91,"phases":5270,"primaryCompletion":4864,"completion":4864,"start":4865,"enrollment":4866,"conditions":5271,"interventions":5272},[],[20,4868,4869,4870],[4680,4872],{"intervention":4749,"totalTrials":112,"cells":5274},{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5281,"PHASE4":5283,"NA":5285},{"trials":5276,"activeCount":83},[],{"trials":5278,"activeCount":83},[],{"trials":5280,"activeCount":83},[],{"trials":5282,"activeCount":83},[],{"trials":5284,"activeCount":83},[],{"trials":5286,"activeCount":83},[5287],{"nctId":4741,"briefTitle":4742,"status":91,"phases":5288,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":4746,"conditions":5289,"interventions":5290},[],[15],[4749,4750,775,4680,4751],{"intervention":4751,"totalTrials":112,"cells":5292},{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5297,"PHASE3":5299,"PHASE4":5301,"NA":5303},{"trials":5294,"activeCount":83},[],{"trials":5296,"activeCount":83},[],{"trials":5298,"activeCount":83},[],{"trials":5300,"activeCount":83},[],{"trials":5302,"activeCount":83},[],{"trials":5304,"activeCount":83},[5305],{"nctId":4741,"briefTitle":4742,"status":91,"phases":5306,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":4746,"conditions":5307,"interventions":5308},[],[15],[4749,4750,775,4680,4751],{"intervention":4762,"totalTrials":112,"cells":5310},{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5315,"PHASE3":5317,"PHASE4":5319,"NA":5321},{"trials":5312,"activeCount":83},[],{"trials":5314,"activeCount":83},[],{"trials":5316,"activeCount":83},[],{"trials":5318,"activeCount":83},[],{"trials":5320,"activeCount":83},[],{"trials":5322,"activeCount":83},[5323],{"nctId":4753,"briefTitle":4754,"status":4755,"phases":5324,"primaryCompletion":4757,"start":4758,"enrollment":4759,"conditions":5325,"interventions":5326},[],[15],[774,4762,775,4680,4711,4702,4763]]